Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Transplantation of an individual's own tissue from one site to another site.
The transference of a part of or an entire liver from one human or animal to another.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
The transference of a kidney from one human or animal to another.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Transference of cells within an individual, between individuals of the same species, or between individuals of different species.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
The transference of a heart from one human or animal to another.
Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.
An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.
The transference of either one or both of the lungs from one human or animal to another.
Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Transference of an organ between individuals of the same species or between individuals of different species.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.
Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.
Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)
Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.
Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).
The return of a sign, symptom, or disease after a remission.
The transference of a pancreas from one human or animal to another.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Elements of limited time intervals, contributing to particular results or situations.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Non-cadaveric providers of organs for transplant to related or non-related recipients.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Immunological rejection of leukemia cells following bone marrow transplantation.
Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Transplantation of tissue typical of one area to a different recipient site. The tissue may be autologous, heterologous, or homologous.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
Providers of tissues for transplant to non-related individuals.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
The administrative procedures involved with acquiring TISSUES or organs for TRANSPLANTATION through various programs, systems, or organizations. These procedures include obtaining consent from TISSUE DONORS and arranging for transportation of donated tissues and organs, after TISSUE HARVESTING, to HOSPITALS for processing and transplantation.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Persons or animals having at least one parent in common. (American College Dictionary, 3d ed)
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.
Transference of fetal tissue between individuals of the same species or between individuals of different species.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.
The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.
The procedure established to evaluate the health status and risk factors of the potential DONORS of biological materials. Donors are selected based on the principles that their health will not be compromised in the process, and the donated materials, such as TISSUES or organs, are safe for reuse in the recipients.
Disorders of the blood and blood forming tissues.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
Transplantation between animals of different species.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Disease having a short and relatively severe course.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
Progenitor cells from which all blood cells derive.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
The grafting of skin in humans or animals from one site to another to replace a lost portion of the body surface skin.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Transference of tissue within an individual, between individuals of the same species, or between individuals of different species.
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
Partial or total replacement of the CORNEA from one human or animal to another.
Transference of brain tissue, either from a fetus or from a born individual, between individuals of the same species or between individuals of different species.
Prospective patient listings for appointments or treatments.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).
Pathological processes of the LIVER.
An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.
The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
A dead body, usually a human body.
Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.
The mechanism by which latent viruses, such as genetically transmitted tumor viruses (PROVIRUSES) or PROPHAGES of lysogenic bacteria, are induced to replicate and then released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell LIPOPOLYSACCHARIDES, glucocorticoid hormones, halogenated pyrimidines, IONIZING RADIATION, ultraviolet light, and superinfecting viruses.
Tissues, cells, or organs transplanted between genetically different individuals of the same species.
A general term for various neoplastic diseases of the lymphoid tissue.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
Organs, tissues, or cells taken from the body for grafting into another area of the same body or into another individual.
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Substances that inhibit or prevent the proliferation of NEOPLASMS.
The transference between individuals of the entire face or major facial structures. In addition to the skin and cartilaginous tissue (CARTILAGE), it may include muscle and bone as well.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.
The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
The process by which organs are kept viable outside of the organism from which they were removed (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Tissue, organ, or gamete donation intended for a designated recipient.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Antibodies produced by a single clone of cells.
Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
The physiological renewal, repair, or replacement of tissue.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
The transfer of leukocytes from a donor to a recipient or reinfusion to the donor.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Antibodies obtained from a single clone of cells grown in mice or rats.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
The procedure of removing TISSUES, organs, or specimens from DONORS for reuse, such as TRANSPLANTATION.
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Infection with ROSEOLOVIRUS, the most common in humans being EXANTHEMA SUBITUM, a benign disease of infants and young children.
Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.
The number of LYMPHOCYTES per unit volume of BLOOD.
Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.
Euploid male germ cells of an early stage of SPERMATOGENESIS, derived from prespermatogonia. With the onset of puberty, spermatogonia at the basement membrane of the seminiferous tubule proliferate by mitotic then meiotic divisions and give rise to the haploid SPERMATOCYTES.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Cells derived from a FETUS that retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.
A partial or complete return to the normal or proper physiologic activity of an organ or part following disease or trauma.
A family composed of spouses and their children.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
A PREDNISOLONE derivative with similar anti-inflammatory action.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
An immunological attack mounted by a graft against the host because of tissue incompatibility when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE.
An individual that contains cell populations derived from different zygotes.
The transference of a complete HAND, as a composite of many tissue types, from one individual to another.
Infections with fungi of the genus ASPERGILLUS.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Methods for maintaining or growing CELLS in vitro.
The period following a surgical operation.
A mutant strain of Rattus norvegicus without a thymus and with depressed or absent T-cell function. This strain of rats may have a small amount of hair at times, but then lose it.
The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
The immune responses of a host to a graft. A specific response is GRAFT REJECTION.
Preservation of cells, tissues, organs, or embryos by freezing. In histological preparations, cryopreservation or cryofixation is used to maintain the existing form, structure, and chemical composition of all the constituent elements of the specimens.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.

oko meduzy mutations affect neuronal patterning in the zebrafish retina and reveal cell-cell interactions of the retinal neuroepithelial sheet. (1/1372)

Mutations of the oko meduzy (ome) locus cause drastic neuronal patterning defect in the zebrafish retina. The precise, stratified appearance of the wild-type retina is absent in the mutants. Despite the lack of lamination, at least seven retinal cell types differentiate in oko meduzy. The ome phenotype is already expressed in the retinal neuroepithelium affecting morphology of the neuroepithelial cells. Our experiments indicate that previously unknown cell-cell interactions are involved in development of the retinal neuroepithelial sheet. In genetically mosaic animals, cell-cell interactions are sufficient to rescue the phenotype of oko meduzy retinal neuroepithelial cells. These cell-cell interactions may play a critical role in the patterning events that lead to differentiation of distinct neuronal laminae in the vertebrate retina.  (+info)

Adult subventricular zone neuronal precursors continue to proliferate and migrate in the absence of the olfactory bulb. (2/1372)

Neurons continue to be born in the subventricular zone (SVZ) of the lateral ventricles of adult mice. These cells migrate as a network of chains through the SVZ and the rostral migratory stream (RMS) into the olfactory bulb (OB), where they differentiate into mature neurons. The OB is the only known target for these neuronal precursors. Here, we show that, after elimination of the OB, the SVZ and RMS persist and become dramatically larger. The proportion of dividing [bromodeoxyuridine (BrdU)-labeled] or dying (pyknotic or terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end-labeled) cells in the RMS was not significantly affected at 3 d or 3 weeks after bulbectomy (OBX). However, by 3 months after OBX, the percentage of BrdU-labeled cells in the RMS decreased by half and that of dying cells doubled. Surprisingly, the rostral migration of precursors continued along the RMS after OBX. This was demonstrated by focal microinjections of BrdU and grafts of SVZ cells carrying LacZ under the control of a neuron-specific promoter gene. Results indicate that the OB is not essential for proliferation and the directional migration of SVZ precursors.  (+info)

Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. (3/1372)

The perivascular implantation of tissue-engineered endothelial cells around injured arteries offers an opportunity to study fundamental vascular physiology as well as restore and improve tissue function. Cell source is an important issue because the ability to implant either xenogeneic or allogeneic cells would greatly enhance the clinical applications of tissue-engineered grafts. We investigated the biological and immunological responses to endothelial cell xenografts and allografts in pigs 4 weeks after angioplasty of the carotid arteries. Porcine or bovine aortic endothelial cells were cultured within Gelfoam matrices and implanted in the perivascular space of 42 injured arteries. Both porcine and bovine endothelial cell grafts reduced the restenosis index compared with control by 54% and 46%, respectively. Perivascular heparin release devices, formulated to release heparin at twice the rate of release of heparan sulfate proteoglycan from endothelial cell implants, produced no significant reduction in the restenosis index. Endothelial cell implants also reduced occlusive thrombosis compared with control and heparin release devices. Host immune responses to endothelial implants were investigated by immunohistochemical examination of explanted devices and by immunocytochemistry of serum samples. The bovine cell grafts displayed infiltration of leukocytes, consisting primarily of lymphocytes, and caused an increase in antibodies detected in serum samples. Reduced cellular infiltration and no humoral response were detected in animals that received allografts. Despite the difference in immune response, the biological effects of xenografts or allografts did not differ significantly.  (+info)

Repopulation of different layers of host human Bruch's membrane by retinal pigment epithelial cell grafts. (4/1372)

PURPOSE: To determine the morphology of human retinal pigment epithelium (RPE) after reattachment to different ultrastructural layers of human Bruch's membrane (BM). METHODS: Bruch's membrane explants were prepared from eyes of 23 human donors (age range, 11-89 years). The basal lamina of the RPE, inner collagenous layer, and elastin layer were removed sequentially by mechanical and enzymatic techniques. First-passage cells of human RPE (15,000 cells/6 mm explant) from three donors (ages, 52, 64, and 80 years) were plated onto different layers of human BM, and the explants were examined by scanning and transmission electron microscopy up to 21 days later. RESULTS: RPE flattened and extended footplates 6 hours after plating onto basal lamina. Cells remained round 6 and 24 hours after plating onto the inner collagenous, elastin, or outer collagenous layer. The RPE cells became confluent 14 days after plating onto basal lamina but did not become confluent up to 21 days after plating onto the inner collagenous or elastin layer. Sparse round cells were observed 21 days after plating onto deeper layers, suggesting extensive loss of RPE. CONCLUSIONS: The morphology and subsequent behavior of the RPE reattached to BM depends on the anatomic layer of BM available for cell reattachment. The results suggest that the ability of transplanted RPE to repopulate BM in age-related macular degeneration and other disorders may depend on the layer of BM available to serve as a substrate for cell reattachment.  (+info)

Transplantation of osteoblast-like cells to the distracted callus in rabbits. (5/1372)

We carried out limb lengthening in rabbits and then transplanted osteoblast-like cells derived from the tibial periosteum to the centres of distracted callus immediately after distraction had been terminated. Two weeks later the transaxial area ratio at the centre of the distracted callus and the bone mineral density (BMD) were significantly higher in the transplanted group, by 21% and 42%, respectively, than in the non-injected group or the group injected with physiological saline (p < 0.05). Callus BMD as a percentage of density in uninvolved bone was also significantly higher in the transplanted group (p < 0.05) than in the other two groups, by 27% and 20% in the second and fourth weeks, respectively (p < 0.05). Mechanically, the callus in the transplanted group tended to be stronger as shown by the three-point bending test although the difference in fracture strength was not statistically significant. Our results show that transplantation of osteoblast-like cells promotes maturity of the distracted callus as observed at the second and fourth weeks after lengthening. The method appears promising as a means of shortening the consolidation period of callus distraction and decreasing complications during limb lengthening with an external fixator.  (+info)

Transplanted hepatocytes proliferate differently after CCl4 treatment and hepatocyte growth factor infusion. (6/1372)

To understand regulation of transplanted hepatocyte proliferation in the normal liver, we used genetically marked rat or mouse cells. Hosts were subjected to liver injury by carbon tetrachloride (CCl4), to liver regeneration by a two-thirds partial hepatectomy, and to hepatocellular DNA synthesis by infusion of hepatocyte growth factor for comparative analysis. Transplanted hepatocytes were documented to integrate in periportal areas of the liver. In response to CCl4 treatments after cell transplantation, the transplanted hepatocyte mass increased incrementally, with the kinetics and magnitude of DNA synthesis being similar to those of host hepatocytes. In contrast, when cells were transplanted 24 h after CCl4 administration, transplanted hepatocytes appeared to be injured and most cells were rapidly cleared. When hepatocyte growth factor was infused into the portal circulation either subsequent to or before cell transplantation and engraftment, transplanted cell mass did not increase, although DNA synthesis rates increased in cultured primary hepatocytes as well as in intact mouse and rat livers. These data suggested that procedures causing selective ablation of host hepatocytes will be most effective in inducing transplanted cell proliferation in the normal liver. The number of transplanted hepatocytes was not increased in the liver by hepatocyte growth factor administration. Repopulation of the liver with genetically marked hepatocytes can provide effective reporters for studying liver growth control in the intact animal.  (+info)

Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. (7/1372)

Myoblasts, the precursors of skeletal muscle fibers, can be induced to withdraw from the cell cycle and differentiate in vitro. Recent studies have also identified undifferentiated subpopulations that can self-renew and generate myogenic cells (Baroffio, A., M. Hamann, L. Bernheim, M.-L. Bochaton-Pillat, G. Gabbiani, and C.R. Bader. 1996. Differentiation. 60:47-57; Yoshida, N., S. Yoshida, K. Koishi, K. Masuda, and Y. Nabeshima. 1998. J. Cell Sci. 111:769-779). Cultured myoblasts can also differentiate and contribute to repair and new muscle formation in vivo, a capacity exploited in attempts to develop myoblast transplantation (MT) for genetic modification of adult muscle. Our studies of the dynamics of MT demonstrate that cultures of myoblasts contain distinct subpopulations defined by their behavior in vitro and divergent responses to grafting. By comparing a genomic and a semiconserved marker, we have followed the fate of myoblasts transplanted into muscles of dystrophic mice, finding that the majority of the grafted cells quickly die and only a minority are responsible for new muscle formation. This minority is behaviorally distinct, slowly dividing in tissue culture, but rapidly proliferative after grafting, suggesting a subpopulation with stem cell-like characteristics.  (+info)

Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemia. (8/1372)

The development of gene-replacement therapy for inborn errors of metabolism has been hindered by the limited number of suitable large-animal models of these diseases and by inadequate methods of assessing the efficacy of treatment. Such methods should provide sensitive detection of expression in vivo and should be unaffected by concurrent pharmacologic and dietary regimens. We present the results of studies in a neonatal bovine model of citrullinemia, an inborn error of urea-cycle metabolism characterized by deficiency of argininosuccinate synthetase and consequent life-threatening hyperammonemia. Measurements of the flux of nitrogen from orally administered 15NH4 to [15N]urea were used to determine urea-cycle activity in vivo. In control animals, these isotopic measurements proved to be unaffected by pharmacologic treatments. Systemic administration of a first-generation E1-deleted adenoviral vector expressing human argininosuccinate synthetase resulted in transduction of hepatocytes and partial correction of the enzyme defect. The isotopic method showed significant restoration of urea synthesis. Moreover, the calves showed clinical improvement and normalization of plasma glutamine levels after treatment. The results show the clinical efficacy of treating a large-animal model of an inborn error of hepatocyte metabolism in conjunction with a method for sensitively measuring correction in vivo. These studies will be applicable to human trials of the treatment of this disorder and other related urea-cycle disorders.  (+info)

Shoukang Zhu, Shanming Deng, Qi Ma, Taifang Zhang, Chunling Jia, Degen Zhuo, Falin Yang, Jianqin Wei, Liyong Wang, Derek M. Dykxhoorn, Joshua M. Hare, Pascal J. Goldschmidt-Clermont and Chunming Dong ...
A primary assumption that guides current approaches to in utero hematopoietic cellular transplantation (IUHCT) is that the early-gestation fetus has an immature...
Cellular therapy is a therapy in which cellular material is inserted into a patient, its means intact, living cells. The main motto of cell therapy is to introduce cells into the body that will grow and replace damaged tissue. Organs and glands are used in cell treatment include brain, pituitary, thyroid, heart, pancreas, adrenals, thymus, liver, kidney, spleen, ovary and testis ...
Nashville Tennessee Endothelial cell transplantation to treat Fuchs Surgeon - Get all of your Endothelial cell transplantation to treat Fuchs Surgery questions answered at one of our Free laser vision correction seminars in Nashville, TN. Click here for more information!
PURPOSE. To evaluate the use of autologous serum (AS) from patients with severe ocular surface disease (OSD) in the development of transplantable corneal and oral epithelial tissue equivalents and to compare it with the use of conventional culture methods by using fetal bovine serum (FBS). METHODS. AS was obtained from patients with severe OSD secondary to Stevens-Johnson syndrome. Corneal and oral epithelial cells were cultivated in medium supplemented with either AS or FBS. Corneal and oral epithelial equivalents were constructed on denuded amniotic membranes. The bromodeoxyuridine (BrdU) ELISA cell proliferation assay and colony-forming efficiency (CFE) of cells cultivated in AS- or FBS-supplemented media were compared. The morphologic characteristics and the basement membrane assembly of cultivated epithelial equivalents were analyzed by light and electron microscopy, as well as by immunohistochemistry. RESULTS. BrdU proliferation assay and CFE analysis showed that human corneal and oral ...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
Skeletal muscle has tissue-specific stem cells named satellite cells. Satellite cells exist in a quiescent state between myofibers and the basal lamina. When skeletal muscle is injured, satellite cells are activated, proliferate, and differentiate into myofibers. It is reported that isolated satellite cells/myoblasts from healthy donors are able to fuse with host dystrophin-deficient myofibers after transplantation via intramuscular injection, and expression of dystrophin at the sarcolemma was observed. Therefore, myoblast transfer is expected to be a promising therapy for DMD. However, the numbers of cells prepared from donors are not adequate for clinical use. To obtain a large number of satellite cells/ myoblasts of good quality, we are developing a method to induce muscle stem cells from human iPS cells. Although autologous cell transplantation needs no immunosuppression, the genes require editing to express dystrophin. In addition, the time and expense required for the process impose a ...
Intramyocardial injections of cultured fetal cardiomyocytes after infarction in female rats in an ischaemia-reperfusion model increased ejection fraction at one month; male cells transplanted into the female hosts were identified at necropsy by detection of the Y chromosome using an in situ hybridisation technique.7 In a mouse model of doxorubicin induced global cardiomyopathy,8 local transplantation of fetal cardiomyocytes can also improve global function, suggesting the intervention of paracrine factors. Comparing intramyocardial injections of cultured fetal cardiomyocytes and allogenic fetal skeletal myoblasts after infarction in rats,9 the functional equivalence of these two types of cells was demonstrated with decreased cavity dilatation and increased ejection fraction of similar magnitude; this anti-remodelling effect was more pronounced for the lowest ejection fractions (, 40%) with an approximately 30% relative increase in ejection fraction without cavity dilatation. Similar results ...
Rajvanshi P, Fabrega A, Bhargava KK, Kerr A, Pollak R, Blanchard J, et al. Rapid clearance of transplanted hepatocytes from pulmonary capillaries in rats indicates a wide safety margin of liver repopulation and the potential of using surrogate albumin particles for safety analysis. J Hepatol 1999; 30: 299-310 ...
TY - CHAP. T1 - Hepatic preconditioning for transplanted cell engraftment and proliferation. AU - Wu, Yao Ming. AU - Gupta, Sanjeev. PY - 2009. Y1 - 2009. N2 - Hepatocyte transplantation has therapeutic potential for multiple hepatic and extrahepatic disorders with genetic or acquired basis. To demonstrate whether cell populations of interest will be effective for clinical applications, it is first necessary to characterize their properties in animal systems. Demonstrating the potential of cells to engraft and proliferate is a critical part of this characterization. Similarly, for stem/progenitor cells, demonstrating the capacity to differentiate along appropriate lineages and generate mature cells that can engraft and proliferate is essential. In various animal models, preconditioning of recipients prior to cell transplantation has been necessary to improve engraftment of cells, to stimulate proliferation of engrafted cells, and to induce extensive repopulation of the host liver by transplanted ...
TY - JOUR. T1 - Differing phagocytic capacities of accessory and main olfactory ensheathing cells and the implication for olfactory glia transplantation therapies. AU - Nazareth, Lynnmaria. AU - Tello Velasquez, Johana. AU - Lineburg, Katie E.. AU - Chehrehasa, Fatemeh. AU - St John, James A.. AU - Ekberg, Jenny A K. PY - 2015/3/1. Y1 - 2015/3/1. N2 - The rodent olfactory systems comprise the main olfactory system for the detection of odours and the accessory olfactory system which detects pheromones. In both systems, olfactory axon fascicles are ensheathed by olfactory glia, termed olfactory ensheathing cells (OECs), which are crucial for the growth and maintenance of the olfactory nerve. The growth-promoting and phagocytic characteristics of OECs make them potential candidates for neural repair therapies such as transplantation to repair the injured spinal cord. However, transplanting mixed populations of glia with unknown properties may lead to variations in outcomes for neural repair. As the ...
Glaucoma is the term used to describe a group diseases characterised by a specific type of damage to the optic nerve head (ONH) known as cupping and a characteristic type of visual field loss. This loss is associated with progressive atrophy and loss of the retinal ganglion cells. Glaucoma is a leading cause of irreversible blindness in the world. This project was aimed at investigating olfactory ensheathing cells (OEC), a population of radial glia proven to be neuroprotective in central and peripheral nerve injury models, and their potential to protect the retinal ganglion cells in glaucoma. We studied the interactions of RGC and OEC in culture. We show that OEC can straighten, ensheath and bundle RGC neurites as well as support the survival of RGC and their synapses in culture. We also show that OEC endocytose dead RGC in culture. We modified a rat model of glaucoma (where paramagnetic microbeads are injected into the anterior chamber of the rat eyes) and characterised the early and late ...
TY - JOUR. T1 - Evidence for active acetylcholine metabolism in human amniotic epithelial cells. T2 - Applicable to intracerebral allografting for neurologic disease. AU - Sakuragawa, Norio. AU - Misawa, Hidemi. AU - Ohsugi, Keiko. AU - Kakishita, Kouji. AU - Ishii, Takashi. AU - Thangavel, Ramasamy. AU - Tohyama, Jun. AU - Elwan, Mohamed. AU - Yokoyama, Yasunobu. AU - Okuda, Osamu. AU - Arai, Hajime. AU - Ogino, Ikuko. AU - Sato, Kiyoshi. PY - 1997/8/22. Y1 - 1997/8/22. N2 - Human amniotic epithelial (HAE) cells have been used for allotransplantation in patients with lysosomal storage disease due to lack of expression of HLA antigens. Previously, we have reported the expression of differentiation markers for both neural stem cells, and neuron and glial cells. In the present study, we investigated the presence of choline acetyltransferase (CHAT) and acetylcholine (ACh) in HAE cells using different experimental approaches. Cultured HAE cells showed strong immunoreactivity against ChAT antibody. ...
Human Amniotic Epithelial Cell Lysate ...
Chen, H.-L., Chen, H.-L., Yuan, R.-H., Wu, S.-H., Chen, Y.-H., Chien, C.-S., Chou, S.-P., Wang, R., Ling, V. and Chang, M.-H. (2012), Hepatocyte transplantation in bile salt export pump-deficient mice: selective growth advantage of donor hepatocytes under bile acid stress. Journal of Cellular and Molecular Medicine, 16: 2679-2689. doi: 10.1111/j.1582-4934.2012.01586.x ...
The second day the conference focused on newer aspects of treatment for heart failure. Philippe Menasche (Paris) described the results of skeletal myoblast transfer in man. Based upon previous studies in animals, they had been able to optimise cell survival of thigh muscle myoblasts grown in culture. After 16 days culture a suspension containing 150 × 106 cells/ml is injected into scar tissue at the time of coronary artery bypass graft surgery (CABG). Although some 90% of these cells die early after transplantation, those that survive remain committed to skeletal muscle form, but are resistant to ischaemia. To date, there is no evidence that skeletal myoblast transplantation leads to the formation of connexin 43 junctions, but arrhythmias remain a potential complication. Nevertheless, initial results in eight patients have shown evidence of improved cardiac function. A trial is proposed which will compare CABG grafting and injection of medium with CABG surgery and transplanted cells in 70-75 ...
Sigma-Aldrich offers abstracts and full-text articles by [Ali Jahed, James W Rowland, Todd McDonald, J Gordon Boyd, Ronald Doucette, Michael D Kawaja].
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Until their disease starts to quiet down. Could be a little challenging. I was trying to make a few incisions here to see if there was another layer interface. But I dont think there is. What we dont want to do is we do not want to perforate. Because that would require tissue. So, I think the emphasis on diseases like Stevens-Johnson need to be in the acute care of these patients. And that really means the hospitals have to have good communication with the ophthalmologist so that there can be aggressive in that early acute phase. When there is actually something we can do for these patients and not in the end stage where theres very little we can offer these patients ...
Translational research for Spinal Cord Injury including cellular transplantation and neural tissue protection,especially as applies to mild hypothermia.
Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penns Abramson Cancer Center (ACC). The team will present the results from its pilot study […]. ...
Rikke Bech, Babak Jalilian, Ralf Agger, Lars Iversen, Mogens Erlandsen, Kristian Otkjaer, Claus Johansen, Søren R. Paludan, Carina A. Rosenberg, Knud Kragballe, Thomas Vorup-Jensen ...
Oct 23, 2008 - Opexa Therapeutics, Inc. (NASDAQ OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoim
This form must be completed when a new malignancy is reported on a Cellular Therapy Essential Data Follow-Up Form (Form 4100). Reported new malignancies should...
TY - JOUR. T1 - Low-dose curcumin stimulates proliferation, migration and phagocytic activity of olfactory ensheathing cells. AU - Velasquez, Johana Tello. AU - Watts, Michelle E.. AU - Todorovic, Michael. AU - Nazareth, Lynnmaria. AU - Pastrana, Erika. AU - Diaz-Nido, Javier. AU - Lim, Filip. AU - Ekberg, Jenny A K. AU - Quinn, Ronald J.. AU - St John, James A.. PY - 2014/10/31. Y1 - 2014/10/31. N2 - One of the promising strategies for neural repair therapies is the transplantation of olfactory ensheathing cells (OECs) which are the glial cells of the olfactory system. We evaluated the effects of curcumin on the behaviour of mouse OECs to determine if it could be of use to further enhance the therapeutic potential of OECs. Curcumin, a natural polyphenol compound found in the spice turmeric, is known for its anti-cancer properties at doses over 10 μM, and often at 50 μM, and it exerts its effects on cancer cells in part by activation of MAP kinases. In contrast, we found that low-dose curcumin ...
Watzlawick R, Rind J, Sena ES, Brommer B, Zhang T, Kopp MA, Dirnagl U, Macleod MR, Howells DW, Schwab JM Olfactory ensheathing cell (OEC) transplantation is …
Olfactory ensheathing cells (OECs) accompany the axons of olfactory receptor neurons, which regenerate throughout life, from the olfactory mucosa into the olfactory bulb. OECs have shown widely varying efficacy in repairing the injured nervous system. Analysis of the transcriptome of OECs will help in understanding their biology and will provide tools for investigating the mechanisms of their efficacy and interactions with host tissues in lesion models. In this study, we compared the transcriptional profile of cultured OECs with that of Schwann cells (SCs) and astrocytes (ACs), two glial cell types to which OECs have similarities. Two biological replicates of RNA from cultured OECs, SCs, and ACs were hybridized to long oligo rat 5K arrays against a common reference pool of RNA (50% cultured fibroblast RNA and 50% neonatal rat brain RNA). Transcriptional profiles were analyzed by hierarchical clustering, Principal Components Analysis, and the Venn diagram. The three glial cell types had similarly
TY - JOUR. T1 - Liver regeneration and energetic changes in rats following hepatic radiation therapy and hepatocyte transplantation by 31P MRSI. AU - Landis, Charles S.. AU - Zhou, Hongchao. AU - Liu, Laibin. AU - Hetherington, Hoby P.. AU - Guha, Chandan. N1 - Publisher Copyright: © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.. PY - 2015/4/1. Y1 - 2015/4/1. N2 - Radiation-induced liver damage (RILD) is a poorly understood and potentially devastating complication of hepatic radiation therapy (RT) for liver cancers. Previous work has demonstrated that hepatocyte transplantation (HT) can ameliorate RILD in rats. We hypothesized that RT inhibits generation of cellular ATP and suppresses hepatic regeneration. Methods: To study the metabolic changes that occur in RILD with and without HT, 31P MRSI data were acquired in rats treated with partial hepatectomy (PH) alone, PH with hepatic irradiation (PHRT) or PHRT with HT (PHRT+HT). Results: Both [γ -ATP] and ATP/Pi 31P MRSI signal ...
TY - JOUR. T1 - Administration of control-released hepatocyte growth factor enhances the efficacy of skeletal myoblast transplantation in rat infarcted hearts by greatly increasing both quantity and quality of the graft. AU - Tambara, Keiichi. AU - Premaratne, Goditha U.. AU - Sakaguchi, Genichi. AU - Kanemitsu, Naoki. AU - Lin, Xue. AU - Nakajima, Hiroyuki. AU - Sakakibara, Yutaka. AU - Kimura, Yu. AU - Yamamoto, Masaya. AU - Tabata, Yasuhiko. AU - Ikeda, Tadashi. AU - Komeda, Masashi. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2005/8/30. Y1 - 2005/8/30. N2 - Background - We investigated whether simultaneous administration of control-released hepatocyte growth factor (HGF) enhances the efficacy of skeletal myoblast (SM) transplantation (Tx) through its antiapoptotic, angiogenic, and antifibrotic effects in myocardial infarction (MI). Methods and Results - Forty-eight Lewis rats with chronic MI were divided into 4 groups. In Group I (n = 14), neonatal SMs (5 × 106) ...
Bullous keratopathy is a condition where corneal endothelial cells, which do not normally proliferate in vivo, are extensively impaired by trauma, disease, surgery or the like and do not longer maintain the transparency of the cornea, leading to edema and turbidity. Kyoto Prefectural University of Medicine and Doshisha University jointly expanded corneal endothelial cells derived from donors and injected them into the anterior chamber of patients with keratopathy. 11 cases of a clinical study now confirmed effectiveness and safety of this treatment.. AMED news release, March 15, 2018. ...
Study Design. Two groups of 6 rats received dorsolateral funiculotomies followed by direct injection of bone marrow stromal Z-IETD-FMK ic50 cells (MSC) or mono-nuclear fraction of bone marrow (mnBM). Animals were killed at 4 or 21 days.. Objective. Cellular transplantation is a promising treatment strategy for spinal cord injury (SCI); however, most cells need to be cultured before transplantation introducing burdensome steps for clinical application. Cells immediately available for transplantation, like mnBM, would be preferable.. Summary of Background Data. Previous studies have shown that MSC transplants promote protection and repair after SCI. MSC are attractive for transplantation because of easy isolation and availability of autologous sources. MSC are derived from whole bone marrow, purified and Elafibranor ic50 expanded in culture for a period of at least 2 weeks. Alternatively, mnBM could be used for transplantation. mnBM derived from bone marrow from through simple centrifugation can ...
View full text. Author: Vácz G, Cselenyák A, Cserép Z, Benkő R, Kovács E, Pankotai E, Lindenmair A, Wolbank S, Schwarz CM, Horváthy DB, Kiss L, Hornyák I, Lacza Z.. Year: 2016. Journal: Interv Med Appl Sci.. Volume: 8. Issue: 4. Pages: H848-H857. doi: 10.1556/1646.8.2016.4.6.. PubMed PMID: 28180006. PubMed Central PMCID: PMC5283775.. Cited: 4. ...
Dedicated to Improving Your Quality of Life through the Use of Cellular Therapy.. We are a team of experts with more than 9 years of experience in the Cellular Therapy field. We provide the highest quality care during your quest to feel your best.. In recent years, there have been many exciting breakthroughs and therapeutic advances using cellular therapy. Our team of world class scientists has developed safe and effective procedures that may help improve your quality of life.. Cellular therapies may repair damaged tissues through various mechanisms of action. It has been proven that stem cells promote vascular repair and release growth factors that may help your own damaged cells and tissues heal.. Before undergoing cellular therapy, you should evaluate the provider. Ask them to describe the scientific support for the procedure and make sure that they are certified to perform it. Rehealths protocols and procedures are certified by COFEPRIS-Mexicos equivalent to US FDA. ...
Cardiomyoplasty is used when cardiac transplantation is not an option and the patient is asymptomatic at rest. The latissimus dorsum muscle is dissected free of its distal insertion and is wrapped around the heart. For the next 2 months, the muscle is stimulated with increasing frequency until it can contract in synchrony with each heartbeat. Six months after surgery, effects of an enhanced cardiac output should be evident.. ...
CAR-T Cells represent the first example of a cellular therapy that has moved from immunological concepts developed in research laboratories to worldwide and large-scale industry-manufacturing of potent therapeutic agents. The bumpy road* for these developments exemplify the many scientific challenges that await developers of this class of therapeutics. While scientific developments continue to occur at a high pace for CAR-T and CAR NK therapies, the race to solve the logistical, medical, financial and societal issues is engaged, with the goal to bring this class of therapeutics to all patients in need of them. CAR-T and CAR NK Cells will likely pave the way for other forms of immune cellular therapies, but also for regenerative medicines. ...
[113 Pages Report] Check for Discount on Global Systemic Mycoses Market Research Report 2017 report by QYResearch Group. In this report, the global Systemic Mycoses market is valued...
Background: The failure of regeneration after spinal cord injury (SCI) has been attributed to axonal demyelination and neuronal death. Cellular replacement and white matter regeneration are both necessary for SCI repair. In this study, we evaluated the co-transplantation of olfactory ensheathing cells (OEC) and embryonic stem (ES) cell-derived motor neurons ...
In the present study, we have shown that Robo proteins are expressed in cultured OECs and exhibit enriched distribution at the leading edge. A Slit-2 gradient indeed strongly repelled the migration of these cultured OECs. To our knowledge, this is the first guidance factor discovered to repel OEC migration. Because Slit-2 is highly expressed in the apical cells of OE, it is likely that it might help Robo-expressing OECs and olfactory axons migrate out of the OE through chemorepulsion during early development. Slits expressing in the OB might also regulate the stop and scattering of OECs that have arrived at the surface of the OB. OECs have been reported to pioneer the olfactory sensory nerves and provide a conductive substrate for the growth of olfactory sensory axons during development (Tennent and Chuah, 1996; Tisay and Key, 1999). An intriguing possibility is that the guidance of OECs by Slits might contribute to the guidance of axons because of the close interaction between neurons and glia. ...
The same three patients were exhibiting signs of sinusitis [13] also. trigeminal nerves FRP (olfactory ensheathing cells and trigeminal Schwann cells, respectively). Bacterias had been degraded by some cells but persisted in additional cells, which resulted in the forming of multinucleated huge cells (MNGCs), with olfactory ensheathing cells less inclined to type MNGCs than Schwann cells. Cap mutant bacteria Double, missing the protein BimA, didnt type MNGCs. These data claim that injuries towards the olfactory epithelium expose the principal olfactory anxious program to bacterial invasion, that may then bring about CNS disease with potential pathogenic outcomes for the glial cells. Writer summary Infections from the central anxious program (CNS), though unusual, are connected with serious mortality and morbidity. can enter the CNS via peripheral nerves increasing between the nose cavity and the mind (bypassing the blood-brain/blood-cerebrospinal Hydroxycotinine liquid barriers). In todays ...
AUTOLOGOUS CHONDROCYTE TRANSPLANTATION Melanie McNeal, PT, CSCS, CFT for patients of DAVID LINTNER, MD Articular cartilage (AC) provides a resilient surface for friction free movement of joints. It must bear ...
There is compelling experimental evidence to show that transplantation of skeletal myoblasts (SMBs) improves the function of failing hearts via paracrine effects. However, clinical application of this strategy has been curtailed due to arrhythmia occurrence and inconsistent outcomes observed in previous clinical trials of intramyocardial (IM) injection of SMBs. Severe inflammation and resultant global reduction of connexin43 have been reported to be causes of the arrhythmogenicity. Recent developments in bioengineering technology enabled production of cell sheets using temperature-responsive culture dishes, which allows retrieval of cells without enzymatic dissociation-related damages. We hypothesized that epicardial attachment of cell sheets would enhance retention, survival, and maintenance of functions of donor SMBs in the heart, with less myocardial injury, and therefore overcome the drawbacks of IM injection.. Methods & Results: After left coronary artery ligation in female Lewis rats, ...
Brigitte Bisaro, Giorgia Mandili, Alice Poli, Andrea Piolatto, Valentina Papa, Francesco Novelli, Giovanna Cenacchi, Marco Forni, Cristina Zanini ...
More precise dosing methods and cellular engineering techniques show promise in the effort to improve treatment of aggressive cancers with personalized cellular therapies, according to new studies from researchers in the ...
Olfactory ensheathing cells (OECs) are a type of specialized glial cell currently considered as having a double function in the nervous system: one regenerative, and another immune. OEC cultures resulted in continuous NF-B activation. The IFN-induced increase of iNOS manifestation was reversed in infected OECs. OECs are susceptible to infection, which can suppress their cytotoxic mechanisms in order to survive. We suggest that, in contrast to microglia, OECs might serve as safe focuses on for pneumococci, providing a more stable environment for evasion of the immune system. Olfactory ensheathing cells (OECs) are a type of specialized glial cell that accompany and ensheath the primary olfactory axons through the olfactory pathway, from your olfactory epithelium to Natamycin small molecule kinase inhibitor the olfactory tract. OECs are crucial for olfactory axonal assistance and outgrowth inside the developing and adult olfactory program1,2. This real estate of OECs makes them a superb candidate ...
View more ,Abstract Background The purpose of this study was to analyze olfactory ensheathing cell (OEC) proliferation and growth on Biosilicate and collagen bioscaffolds, and to determine whether the application of laser phototherapy would result in increased OEC proliferation on the scaffolds. The use of bioscaffolds is considered a promising strategy in a number of clinical applications where tissue healing is suboptimal. As in vitro OEC growth is a slow process, laser phototherapy could be useful to stimulate proliferation on bioscaffolds. Methods OEC cells were seeded on the Biosilicate and collagen scaffolds. Seeded scaffolds were irradiated with a single exposure of 830-nm laser. Nonirradiated seeded scaffolds acted as negative controls. Cell proliferation was assessed 7 days after irradiation. Results OECs were successfully grown on discs composed of a glass-ceramic and collagen composite. Laser irradiation produced a 32.7% decrease and a 13.2% increase in OEC proliferation on ...
TY - JOUR. T1 - Activation of the Wnt/β-catenin signaling reporter in developing mouse olfactory nerve layer marks a specialized subgroup of olfactory ensheathing cells. AU - Wang, Ya Zhou. AU - Molotkov, Andrei. AU - Song, Lanying. AU - Li, Yunhong. AU - Pleasure, David E. AU - Zhou, Chengji. PY - 2008/11. Y1 - 2008/11. N2 - Wnt reporter TOPgal mice carry a β-galactosidase (βgal) gene under the control of the Wnt/β-catenin signaling responsive elements. We found that the intensely immunolabeled βgal+ cells were co-immunolabeled with Nestin and formed a tangentially oriented single-cell layer in the connecting or docking zone where the olfactory sensory axons attached to the brain surface during mid-gestation. During early postnatal development, βgal+ cells were located in the inner olfactory nerve layer (ONLi) and co-labeled with olfactory ensheathing cell (OEC) markers S100β and NPY but not with lineage-specific markers for neurons, oligodendrocytes, astrocytes, and microglia, ...
Cell transplantation therapy is emerging as a promising mode of treatment following myocardial infarction. Of the various cell types that can potentially be used for transplantation, autologous skeletal myoblasts appear particularly attractive, because this would avoid issues of immunogenicity, tumorigenesis, ethics and donor availability. Additionally, skeletal myoblasts display much higher levels of ischemic tolerance and graft survival compared to other cell types. There is some evidence for improvement in heart function with skeletal myoblast transplantation. However, histological analysis revealed that transplanted myoblasts do not transdifferentiate into functional cardiomyocytes in situ. This is evident by the lack of expression of cardiac-specific antigens, and the absence of intercalated disc formation. Instead, there is differentiation into myotubes that are not electromechanically coupled to neighboring cardiomyocytes. This could in turn limit the clinical efficacy of treatment. This ...
After scientists injected paralyzed dogs at their injury sites with so-called olfactory ensheathing cells (OEC) taken from the linings of their noses, some were eventually able to walk. All the animals in the study suffered spinal injuries which prevented them from using or feeling anything in their hind legs.. Our findings are extremely exciting because they show for the first time that transplanting these types of cell into a severely damaged spinal cord can bring about significant improvement, study author Robert Franklin, a regeneration biologist at the Wellcome Trust-MRC Stem Cell Institute, said in a press release. Were confident that the technique might be able to restore at least a small amount of movement in human patients with spinal cord injuries but thats a long way from saying they might be able to regain all lost function.. YAY Science!. Now it seems the treatment has yet to be refined further but read the article and check out the quick video clip below.. ...
By: Dominik Zbogar This is a summary of a paper by researchers in Poland. Original article: Pawel Tabakow et al. (2014). Functional regeneration of supraspinal connections in a patient with transected spinal cord following transplantation of bulbar olfactory ensheathing cells Read More…. ...
Full time, Fixed term for 1 Year). The fellow will work full-time towards an MD(res) or PhD degree under the supervision of Dr. S. Saadoun and Prof. M.C. Papadopoulos within the Department of Neurosurgery. The project involves culturing human olfactory ensheathing cells, from olfactory bulbs, and implanting them into injured human spinal cord to promote neurological recovery.. National Training Number in Neurosurgery and successful attainment of at least ST4 level clinical training are essential requirements. Practical laboratory experience in cell culture and cell-based assays are desirable. The fellow will participate in the neurosurgery registrar on call rota and in daily clinical neurosurgery teaching.. For further information about this position, and to apply, visit ...
FP4,,2.5,University of Newcastle upon Tyne(UK),Università degli Studi di Torino(IT),Johann-Wolfgang-Goethe Universität Frankfurt(DE),MRC Clinical Sciences Centre(UK),Hebrew University of Jerusalem The Authority for Research and Development(IL),Rheinische Friedrich-Wilhelms-Universität Bonn(DE),Tel Aviv University(IL),Università degli Studi di Trieste(IT),Istituto Nazionale per la Ricerca sul Cancro(IT)
De Potter, Patrick. Clinical case--photo essay. Primary cyst of the iris pigment epithelium.. In: Bulletin de la Société belge dophtalmologie, , no. 307, p. 63-4 (2008 ...
Left ventricular function changes after cardiomyoplasty in patients with dilated cardiomyopathy.: Dynamic cardiomyoplasty has been reported in the treatment of
Immortalized hepatocytes are an attractive cell source for hepatocyte transplantation and gene transfer. We compared the phenotype and immunogenicity of freshly isolated (FIH) and immortalized (IMH) rat hepatocytes. Effect of culture and proinflammatory cytokines (TNF-agr, IFN-ggr) was studied on phenotype. FIH were isolated by collagenase digestion. Two SV40 immortalized hepatocyte cell lines were tested (RH1 and P9). Immunophenotyping was performed by FACS analysis using anti-rat-specific antibodies. Immunogenicity was evaluated by a mixed lymphocyte hepatocyte reaction (MLHR). FIH suspension was an almost homogeneous parenchymal cell population with few (1-2%) CD8+ cells. FIH showed a positive staining for ICAM-1 (20-35%) and for Class I (RT1A, 30-60%) but no staining for Class II (RT1B). After 48 h of culture, the already ICAM-1-positive cells were more strongly stained and additionally 3.6% of the cells (possibly endothelial cells) were Class II positive. IMH showed a consistent expression ...
Summary of Facts and Submissions. I. European patent application No. 00 948 918.8 with the title Muscle cells and their use in cardiac repair filed as a International application PCT/US 00/20129 was published under No. WO 01/07568. It was refused by the examining division in a decision dated 15 September 2006.. II. The decision of the examining division was taken on the basis of a main request and seven auxiliary requests which were all found to lack of novelty.. Claim 1 of said main request read as follows:. 1. A transplantable composition comprising isolated adult skeletal myoblast cells and isolated fibroblast cells, wherein the composition comprises from 20 to 70% skeletal myoblast cells. (see decision of the examining division, section X). The examining division observed, in particular, that document (4) on file (infra) described a composition of skeletal myoblast and fibroblast cells which were adult cells since the donor was identified as the subject of myocardial treatment. The ...
E barriers to cellular therapy. Several recent studies on solid extra-cranial neoplasms have shown that strategic timing of chemotherapy and immunotherapy,
What is a peptide? Learn about our peptide research, synthesis and mapping for treatments as well as the science behind cellular therapy.
Chengdu Biopurify offers Retrorsine [480-54-6] - Synonym name: Beta-Longilobine Catalogue No.:... Customizes high quality Phytochemicals, from grams to kilograms, GMP is available. Offers compound library and high quality Herb Extracts.
Cellular therapy is an emerging and evolving field. Through these Common Standards, FACT is expanding its services to facilities utilizing cellular therapy products to improve outcomes in patients suffering from a variety of diseases and conditions. Ideally, various discipline-specific or product specific standards would be added in the future with the input, collaboration, and acceptance of those experts actively involved in the field and their clinical and laboratory programs that volunteer to comply with them. These Common Standards are not intended to apply to hematopoietic cellular therapy programs or to cord blood banks. More detailed and specific standards already exist for both these disciplines, and FACT accreditation based on these specific standards is available.. Obtain Common Standards. ...
Long noncoding RNA lncHand2 promotes liver repopulation via c-Met signaling. Wang Y, Zhu P, Wang J, Zhu X, Luo J, Meng S, Wu J, Ye B, He L, Du Y, He L, Chen R, Tian Y, Fan Z. J Hepatol. 2018 Oct;69(4):861-872. doi: 10.1016/j.jhep.2018.03.029. Epub 2018 Apr 11. ...
Professor Gupta, a virologist, was the lead author in a study which made headlines this year reporting that a second HIV-infected person was
... (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ... See also: List of conditions treated with hematopoietic stem cell transplantation. Indications[edit]. Indications for stem cell ... Cutler C, Antin JH (2001). "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. ...
Hematopoietic cell transplantation[edit]. On January 13, 2011, City of Hope performed its 10,000th hematopoietic stem cell ... peripheral blood stem cells collected by apheresis, and umbilical cord stem cells.[9] ... Southern California Islet Cell Consortium, Islet Cell Transplant Center, Juvenile Diabetes Research Foundation. ... By 2016, this has grown to over 13,000 stem cell transplants. National Comprehensive Cancer Network[edit]. City of Hope is a ...
Islet cell transplantation[edit]. Main article: Islet cell transplantation. Islet cell transplantation may be an option for ... Stem cells[edit]. Pluripotent stem cells can be used to generate beta cells but previously these cells did not function as well ... involving an expansion of autoreactive CD4+ T helper cells and CD8+ T cells, autoantibody-producing B cells and activation of ... Hatipoglu, B (December 2016). "Islet Cell Transplantation and Alternative Therapies". Endocrinology and Metabolism Clinics of ...
Stem cell transplantation[edit]. In 2007, Timothy Ray Brown,[12] a 40-year-old HIV-positive man, also known as "the Berlin ... One study done in 2011 achieves successful CD4+ T-cell reconstitution as a result of CCR5Δ32/Δ32 stem cell transplantation at ... This novel cell-based therapy uses irradiated SupT1 cells as a decoy target for HIV to prevent CD4+ T cell depletion as well as ... Stem cell based gene therapy[edit]. In the past 7 years, scientists have been using different approaches of stem cell based ...
2019-03-19: Cell Transplantation. *2019-03-14: Journal of Speech, Language, and Hearing Research ...
"Seminars in Cell & Developmental Biology. 17 (6): 667-74. doi:10.1016/j.semcdb.2006.11.003. PMC 2705932. PMID 17116414.. ... Transplantation. 20 (9): 1777-9. doi:10.1093/ndt/gfh961. PMID 15998650.. ... Heiner I, Eisfeld J, Lückhoff A (2004). "Role and regulation of TRP channels in neutrophil granulocytes". Cell Calcium. 33 (5-6 ... "Subunit composition of mammalian transient receptor potential channels in living cells". Proceedings of the National Academy ...
Islet cell transplantation *see also digestive system procedures. Pituitary. *Hypophysectomy. *Transsphenoidal surgery * ...
Islet cell transplantation *see also digestive system procedures. Pituitary. *Hypophysectomy. *Transsphenoidal surgery * ...
Robert J. Soiffer (17 November 2008). Hematopoietic Stem Cell Transplantation. Springer. ISBN 978-1-934115-05-3. Retrieved 23 ... as well as abnormal looking cells (dysplasia) in at least one type of blood cell. CMML shows characteristics of a ... In adults, blood cells are formed in the bone marrow, by a process that is known as haematopoiesis. In CMML, there are ... Haematopoietic stem cell transplant remains the only curative treatment for CMML. However, due to the late age of onset and ...
"Stem cell transplantation for neuroblastoma". Bone Marrow Transplantation. 41 (2): 159-65. doi:10.1038/sj.bmt.1705929. PMC ... "Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma". Biology of Blood and Marrow Transplantation. ... Observation, surgery, radiation, chemotherapy, stem cell transplantation[1]. Prognosis. US five-year survival ~95% (, 1 year ... A haploidentical stem cell transplant, that is, donor cells derived from parents, is being studied in those with refractory or ...
June 2008). "Stem cell transplantation for primary immunodeficiencies". Bone Marrow Transplant. 41 Suppl 2: S83-6. doi:10.1038/ ... cell responses to mitogens and allogeneic cells, cytokine production by cells Tests for B cell function: antibodies to routine ... natural killer cells and monocytes (CD15+), as well as activation markers (HLA-DR, CD25, CD80 (B cells). Tests for T cell ... Virus-specific T-Lymphocytes (VST) therapy is used for patients who have received hematopoietic stem cell transplantation that ...
On the cell surface, these proteins are bound to protein fragments (peptides) that have been exported from within the cell. MHC ... "Kidney Transplantation: Past, Present, and Future. University of Michigan Medical Center/Stanford University. Retrieved 14 Dec ... cell surface. • endoplasmic reticulum. • MHC class I protein complex. • ER to Golgi transport vesicle membrane. • integral ... regulation of T cell anergy. • viral process. • regulation of interleukin-6 production. • neutrophil degranulation. • positive ...
Cell. 66 (4): 807-15. doi:10.1016/0092-8674(91)90124-H. PMID 1715244. S2CID 22094672. Fegan, A; White, B; Carlson, JC; Wagner, ... Transplantation. 64 (3): 436-43. doi:10.1097/00007890-199708150-00012. PMID 9275110. Liu J, Farmer JD, Lane WS, Friedman J, ...
... dendritic cells) and Lymphoid lineage cells (T-cells, B-cells, NK-cells). The chemorepulsion of immune cells was first ... Head, JR; Billingham RE (1985). "Immune privilege in the testis:evaluation of potential local factors for transplantation". ... Cancer cells leverage the chemorepulsion of immune cells to evade recognition and destruction by immune cells. Without a ... Other innate leukocytes include natural killer cells, mast cells, eosinophils, basophils, macrophages, and dendritic cells. ...
Patients after hematopoietic stem cell transplantation (HSCT) are at a higher risk for oral squamous cell carcinoma. Post-HSCT ... Squamous-cell carcinoma is a cancer of the squamous cell - a kind of epithelial cell found in both the skin and mucous ... to identify and attack specific cancer cells without harming normal cells." Some targeted therapy used in squamous cell cancers ... Like any cancer, metastasization affects many areas of the body, as the cancer spreads from cell to cell and organ to organ. ...
ATP and adenosine are released in high concentrations after catastrophic disruption of the cell, as occurs in necrotic cell ... Transplantation. 57 (2): 211-7. doi:10.1097/00007890-199401001-00010. PMID 8310510. Kalogeris T, Baines CP, Krenz M, Korthuis ... are molecules within cells that are a component of the innate immune response released from damaged or dying cells due to ... and it can lead to increased expression of cell adhesion molecules (ICAM-1, VCAM-1) on endothelial cells. DNA and RNA: The ...
Scripps Center for Organ and Cell Transplantation. *Comprehensive cancer care at Scripps Cancer Center ...
Stem cell transplantation is being studied and has shown promising results in certain cases.[50] ... A test taking measurements on maturity levels, count, and size of blood cells.[28][37] Targeted cells include: red blood cells ... Aplastic anaemia causes a deficiency of all blood cell types: red blood cells, white blood cells, and platelets.[citation ... Dendritic cells, T-cells, and B-cells.[53] In the presence of 1,25-(OH)2D3, the immune system's production of inflammatory ...
Cell Transplantation. 21 (9): 1997-2008. doi:10.3727/096368911X637452. PMID 22469297. S2CID 21603693. Zhao, Dawen; Richer, ... Grazing copepods release any phytoplankton cells that flash, unharmed; if they were eaten they would make the copepods glow, ... Harvey, E.N. (1932). "The evolution of bioluminescence and its relation to cell respiration". Proceedings of the American ... Small extracellularly secreted molecules stimulate the bacteria to turn on genes for light production when cell density, ...
Stem cell transplantation is an important avenue for SCI research: the goal is to replace lost spinal cord cells, allow ... Types of cells being researched for use in SCI include embryonic stem cells, neural stem cells, mesenchymal stem cells, ... olfactory ensheathing cells, Schwann cells, activated macrophages, and induced pluripotent stem cells. Hundreds of stem cell ... Young W (2015). "Electrical stimulation and motor recovery". Cell Transplantation. 24 (3): 429-46. doi:10.3727/096368915X686904 ...
Cell Transplantation. 26 (9): 1560-1571. doi:10.1177/0963689717721234. PMC 5680957. PMID 29113464. Accessed September ... In 2016 work published showing that it can reverse impaired calcium signalling in steatotic liver cells, which, in turn, might ... Molecular Cell Research. 1863 (9): 2135-46. doi:10.1016/j.bbamcr.2016.05.006. PMID 27178543. Tushuizen ME, Bunck MC, Pouwels PJ ... "One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 ...
Wang, Shaocheng (2019). "Historical Review: Opiate Addiction and Opioid Receptors". Cell Transplantation. 28 (3): 233-238. doi: ...
... efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: A ... In T-cells, activation of the T-cell receptor normally increases intracellular calcium, which acts via calmodulin to activate ... "Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation". Pediatric Transplantation. ... The drug can also be sold as a topical medication in the treatment of T-cell-mediated diseases such as eczema and psoriasis. ...
"Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury". Cell Transplantation. 22 (9): ... "Paralyzed man recovers some function following transplantation of OECs and nerve bridge". EurekAlert!. 20 October 2014. Ben ...
"Organ transplantation". Retrieved December 6, 2012. Nicol, Caitrin (Fall 2007). "Shot in the Dark". The New Atlantis. Schulman ... It has featured articles on subjects like Facebook, cell phones, multitasking, e-readers, GPS and navigation, and virtual ... "Stem cell research". Retrieved December 6, 2012. "Assisted reproductive technologies". Retrieved December 6, 2012. "Cloning". ... The journal has published widely on bioethics, including issues such as stem cell research, assisted reproduction, cloning, ...
Renal transplantation. Sickle cell anemia. Toxins, including ifosfamide (more commonly causing pRTA than dRTA), lithium ... Cell Biol. 37 (6): 1151-61. doi:10.1016/j.biocel.2005.01.002. PMID 15778079. Buckalew VM Jr (1989). "Nephrolithiasis in renal ... Distal RTA is characterized by a failure of acid secretion by the alpha intercalated cells of the cortical collecting duct of ... 1997). "Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene ...
Gershon, R. K. (1975). "A disquisition on suppressor T cells". Transplantation Reviews. 26: 170-185. doi:10.1111/j.1600-065x. ... The T cell population causing this down-regulation was called suppressor T cells and was intensively studied for the following ... Production of IL-10 induces the formation of another population of regulatory T cells called Tr1. Tr1 cells are dependent on IL ... "Connecting the mechanisms of T-cell regulation: dendritic cells as the missing link". Immunological Reviews. 236: 203-218. doi: ...
Cell Transplantation. 21 (9): 1997-2008. doi:10.3727/096368911X637452. PMID 22469297. S2CID 21603693. Zhao, Dawen; Richer, ... When luciferin reaches cells that have been altered to carry the firefly gene, those cells emit light. The BLT inverse problem ... using a bioluminescent cancer cell line), and reconstitution kinetics (using bioluminescent stem cells). Researchers at UT ... The technique requires luciferin to be added to the bloodstream, which carries it to cells throughout the body. ...
"Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury". Cell Transplantation. 22 (9): ... Stem cells are cells that can differentiate to become different types of cells. The hope is that stem cells transplanted into ... Types of cells being researched for use in SCI include embryonic stem cells, neural stem cells, mesenchymal stem cells, ... olfactory ensheathing cells, Schwann cells, activated macrophages, and induced pluripotent stem cells. When stem cells are ...
T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer ... T Cells to protect tumour cells. Nature Communications. March 2018, 9 (1): 948. PMC 5838096. PMID 29507342. doi:10.1038/s41467- ... 细胞毒性T细胞(CTLs, killer T cells)负责杀伤被病毒感染的细胞和癌细胞,在对器官移植的免疫排斥中也有参与。其特点在于细胞表面的CD8蛋白质。它通过识别所有有核细胞表
T. Devos u. a.: Occurrence of autoimmunity after xenothymus transplantation in T-cell-deficient mice depends on the thymus ... B. C. Giovanella u. a.: Development of invasive tumors in the nude mouse after injection of cultured human melanoma cells. In: ... L. Miers u. a.: Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth ... D. Kong u. a.: Establishment and characterization of human pancreatic adenocarcinoma cell line in tissue culture and the nude ...
... cells in destroying these B cells. When an NK cell latched onto the cap, it had an 80% success rate at killing the cell. In ... It is also used as induction therapy in highly sensitized patients going for kidney transplantation. The use of rituximab has ... The antibody binds to the cell surface protein CD20. CD20 is widely expressed on B cells, from early pre-B cells to later in ... It induces apoptosis of CD20+ cells.. The combined effect results in the elimination of B cells (including the cancerous ones) ...
Polymorphonuclear cells also infiltrate the epithelium, and chronic inflammatory cells infiltrate the lamina propria. Atrophic ... organ transplantation and use of indwelling catheters). Oral candidiasis has been recognized throughout recorded history. The ... Apart from true hyphae, Candida can also form pseudohyphae - elongated filamentous cells, lined end to end. As a general rule, ... Smears and biopsies are usually stained with periodic acid-Schiff, which stains carbohydrates in fungal cell walls in magenta. ...
Wu DC, Boyd AS, Wood KJ (2007). "Embryonic stem cell transplantation: potential applicability in cell replacement therapy and ... Gahrton G, Björkstrand B (2000). "Progress in haematopoietic stem cell transplantation for multiple myeloma". J Intern Med 248 ... Lindvall O (2003). "Stem cells for cell therapy in Parkinson's disease". Pharmacol Res 47 (4): 279-87. PMID 12644384. ... "Researchers find new method for turning adult cells into stem cells". Amherst Daily News. Canadian Press. 2009-01-03. Vaadatud ...
... discovered by Paul Ehrlich in 1908 after he observed that bacteria took up toxic dyes that human cells did not. The first major ...
In 1975, association with "HL-A1,8" (Current name: HLA A1-B8) was confirmed by serological typing of cells from myasthenics.[11 ... "Celiac disease autoantibodies in severe autoimmune liver disease and the effect of liver transplantation". Liver Int. 28 (4): ... These chromosome chimerize within the reproductive cells of each parent which are then passed to the developing person during ... make it useful for making cell lines that can be used to test serotyping antibodies. As a result, HLA-A1 and B8 produce some of ...
Today, bone marrow transplantation still offers the only cure for sickle cell disease. Members of Kappa Alpha Psi reach out to ... Jude is the first known hospital in the world to cure sickle cell disease through bone marrow transplantation. ... Members of Kappa Alpha Psi have committed to raise $500,000 in support of the hospital's sickle cell program. St. Jude has one ... Since that time, members across the country have joined in the fight against pediatric cancer, sickle cell disease, and other ...
... pus cells in the urine (pyuria) or cancer cells in the urine. A 24-hour urine collection can be used to quantify daily protein ... Renal transplantation replaces kidney function by inserting into the body a healthier kidney from an organ donor and inducing ... An erythropoetin stimulating agent may be required to ensure adequate production of red blood cells, activated vitamin D ... Nephrologists may further sub-specialise in dialysis, kidney transplantation, chronic kidney disease, cancer-related kidney ...
Fageeh, W.; Raffa, H.; Jabbad, H.; Marzouki, A. (2002). "Transplantation of the human uterus". International Journal of ... Further in the future, stem cell biotechnology may also make this possible, with no need for anti-rejection drugs. ... See also: Transgender pregnancy, Uterus transplantation § Application on transgender women, and Male pregnancy § Humans ...
Wu J, Zern MA (2000). "Hepatic stellate cells: a target for the treatment of liver fibrosis". Journal of Gastroenterology. 35 ( ... Liver transplantation may be a valid option if no improvement occurs.[33] ... Vitamin K prevents hypoprothrombinemia in rats and can sometimes control the increase in plasma/cell ratios of vitamin A.[49] ... Levine PH, Delgado Y, Theise ND, West AB (February 2003). "Stellate-cell lipidosis in liver biopsy specimens. Recognition and ...
2008). "Hand Transplantation: The Innsbruck Experience". Transplantation of Composite Tissue Allografts. pp. 234-250. doi: ... Hand transplantation is a surgical procedure to transplant a hand from one human to another. The "donor" hand usually comes ... On October 26, 2016, the Director of hand transplantation at UCLA, Dr. Kodi Azari, and his team,[14] performed a hand ... "Hand transplantation" - news · newspapers · books · scholar · JSTOR (April 2017) (Learn how and when to remove this template ...
... called matrix-associated autologous chondrocyte transplantation (MACT), grows the patient's cells in a 3D matrix of resorbable ... Then these cells are injected into the patient. These cells are held in place by a small piece of soft tissue from the tibia, ... 10,000 cells are harvested and grown in vitro for approximately six weeks until the population reaches 10-12 million cells. ... The cells grow in self-organized spheroid matrices which are implanted via injected fluid or inserted tissue matrix. For years ...
... platelet activation in vascular disease and stem cell transplantation in cancer patients. As an endocrinologist he has an ... The staging and prognostic value of subset markers on CD8 cells in HIV disease. In Janossy G, Autran B. Miedema F (eds): ... His interest in immunology has led to publications in HIV disease, cellular activation and natural killer cell function, tumor ... Enumeration of CD4+ T-cells in the peripheral blood of HIV-infected patients: interlaboratory study of the FACSCount system. ...
குருதி மாற்றீடு, உறுப்பு மாற்றீடு (Organ transplantation) போன்ற சந்தர்ப்பங்களிலும் நோய்த் தொற்றுள்ள குருதி மூலம் டெங்குத் ... Cell. Mol. Life Sci. 67 (16): 2773-86. doi:10.1007/s00018-010-0357-z. பப்மெட்:20372965. ...
The inflammatory cells involved include neutrophil granulocytes and macrophages, two types of white blood cells. Those who ... Stopping smoking, respiratory rehabilitation, lung transplantation[2]. Medication. Vaccinations, inhaled bronchodilators and ... Several new long-acting agents are under development.[2] Treatment with stem cells is under study.[201] While there is ... Part of this cell response is brought on by inflammatory mediators such as chemotactic factors. Other processes involved with ...
heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules. • cell recognition. • homophilic cell adhesion via ... Transplantation. - 2005. - Т. 79, № 3. - С. 282-288. - DOI:10.1097/01.TP.0000149506.61000.86. - PMID 15699757. ... heterotypic cell-cell adhesion. • positive regulation of transforming growth factor beta production. • cell-cell adhesion. • ... cell adhesion molecule binding. • protein binding involved in heterotypic cell-cell adhesion. • glycosylated region protein ...
Updated: 16 December 2013 Why Perform a Stem Cell Transplant?. *↑ Bone Marrow Transplantation and Peripheral Blood Stem Cell ... "Journal of Stem Cells and Regenerative Medicine.. *↑ "Index of CD34+ Cells and Mononuclear Cells in the Bone Marrow of Spinal ... 2] These cells are produced from the fusion of an egg and sperm cell. Cells produced by the first few divisions of the ... "Core transcriptional regulatory circuitry in human embryonic stem cells". Cell 122 (6): 947-56. 2005. doi:10.1016/j.cell. ...
For a long time, the most efficient approach had been to use bone marrow graft, or hematopoietic stem cell transplantation. ... Because of all these reasons, bone marrow grafts or hematopoietic stem cell transplantation have seen a decrease in their ... The matrix surrounds the cells of the body in an organized meshwork and functions as the glue that holds the cells of the body ... long term follow-up on patients undergone to hematopoietic stem cell transplantation, Minerva Pediatr. 2013 Oct;65(5):487-96. ...
... surgical techniques are used to remove an invasive malignancy that extends to the clitoris. Standard surgical procedures are followed in these cases. This includes evaluation and biopsy. Other factors that will affect the technique selected are age, other existing medical conditions, and obesity. Other considerations are the probability of extended hospital care and the development of infection at the surgical site.[3] The surgery proceeds with the use of general anesthesia, and prior to the vulvectomy/clitoridectomy an inguinal lymphyadenectomy is first done. The extent of the surgical site extends one to two centimeters beyond the boundaries of malignancy. Superficial lymph nodes may also need to be removed. If the malignancy is present in muscular tissue in the region, it is also removed. In some cases, the surgeon is able to preserve the clitoris though the malignancy may be extensive. The cancerous tissue is removed and the incision is closed.[3] Post operative care may ...
Increased migration of cord blood-derived CD34+ cells, as compared to bone marrow and mobilized peripheral blood CD34+ cells ... KK Ballen, F Verter and J Kurtzberg Umbilical cord blood donation: public or private? Bone Marrow Transplantation (2015), 1-8 ... Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proceedings of the ...
Side effects of cell transplantationEdit. A study has shown that cell transplantation may cause an increase in body temperature ... Transplantation of stem cells is also known to cause toxicity and graft-versus-host disease (GVHD). Apoptotic cells have been ... Pessach I, Shimoni A, Nagler A (November 2012). "Apoptotic cells in allogeneic hematopoietic stem cell transplantations: " ... after transplantation.[3] The inability of these cells to sustain after transplantation is a result of inflammation, the ...
The earliest examples of this involved transplantation experiments (technically creating chimeras) where cells from a blastula ... The 46/47 annotation indicates that the XY cells have the normal number of 46 total chromosomes, and the XXY cells have a total ... After further rounds of replication, this cell would result in a patch, or "clone" of cells mutant for the allele being studied ... they can be used to determine the tissue or cell type in which a given gene is required and to determine whether a gene is cell ...
However, larger or deeper ulcers often require the presence of blood vessels to supply inflammatory cells. White blood cells ... In case of progressive or non-healing ulcers, surgical intervention by an ophthalmologist with corneal transplantation may be ... An ulcer of the cornea heals by two methods: migration of surrounding epithelial cells followed by mitosis (dividing) of the ... Surgery in the form of corneal transplantation (penetrating keratoplasty) is usually necessary to save the eye. ...
Class III: LDLR does not properly bind LDL on the cell surface because of a defect in either apolipoprotein B100 (R3500Q) or in ... April 2000). "Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to- ... Class II: LDLR is not properly transported from the endoplasmic reticulum to the Golgi apparatus for expression on the cell ... It has been suggested that PCSK9 causes FH mainly by reducing the number of LDL receptors on liver cells.[13] ...
Hyman B, Van Hoesen GW, Damasio A, Barnes C. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation" ... Hyman B, Van Hoesen GW, Damasio A, Barnes C (1984). "Alzheimer's disease: Cell-specific pathology isolates the hippocampal ... scientific validation of the linkage between feelings and the body by highlighting the connection between mind and nerve cells ...
május 1.). „Transplantation of Living Nuclei From Blastula Cells into Enucleated Frogs' Eggs". Proc Natl Acad Sci U S A. 38 (5 ... 2006) „From Nuclear Transfer to Nuclear Reprogramming: The Reversal of Cell Differentiation". Annual Review of Cell and ... 2008) „Sir John Gurdon: Godfather of cloning". The Journal of Cell Biology 181 (2), 178-179. o. DOI:10.1083/jcb.1812pi. PMID ... 2004-ben a részben általa alapított és 2002-ig általa vezetett Institute for Cell Biology and Cancer sejt- és rákkutatással ...
"Intraspinal stem cell transplantation for amyotrophic lateral sclerosis". Annals of Neurology. 79 (3): 342-53. doi:10.1002/ana. ... Prion-like propagation of misfolded proteins from cell to cell may explain why ALS starts in one area and spreads to others.[27 ... One 2016 review of stem-cell therapy trials found tentative evidence that intraspinal stem cell implantation was relatively ... "Cell Death & Disease. 9 (3): 327. doi:10.1038/s41419-017-0022-7. PMC 5832427. PMID 29491392.. ...
Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ... See also: List of conditions treated with hematopoietic stem cell transplantation. Indications[edit]. Indications for stem cell ... Cutler C, Antin JH (2001). "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. ...
Current research in Stem Cell Transplantation (SCT) focuses on improving transplant outcome through immune manipulations using ...
This article explores the process of transplantation, how to choose a donor, and the risks involved with such a procedure. Read ... Hematopoietic stem cell transplantation is approved for use in treating some types of cancer and is an experimental treatment ... While the therapy is a form of stem cell transplantation, the stem cells are not the main part of the story. In fact, the key ... Stem cells are cells that have the ability to develop into a variety of different specialist cells within the body. ...
Hematopoietic cell transplantation for tolerance induction. In: Lanza R.P., Chick W.L. (eds) Yearbook of Cell and Tissue ... 1992) Donor dendritic cells repopulation in recipients after rat-to-mouse bone marrow transplantation. Lancet 339: 1610-1611. ... Graft Versus Host Disease Hematopoietic Cell Transplantation Allograft Survival Donor Bone Marrow Renal Allograft Survival ... Yearbook of Cell and Tissue Transplantation 1996-1997 pp 287-290 , Cite as ...
Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and ... Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell ... Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive ... Cell Transplantation. ISSN 0963-6897 (Print); ISSN 1555-3892 (Online) Visit publication homepage ...
Islet cell transplantation is an attractive alternative therapy to conventional insulin treatment or vascularized whole ... pancreas transplantation for type 1 diabetic patients. It represents a successful example of somatic cell therapy in humans ... Transplantation consists of a simple injection of few milliliter-purified tissue in the portal vein through a percutaneous ... risk of recurrent hypoglycemia and of diabetic complications are also seen as important benefits of islet cell transplantation ...
Hematopoietic stem cell transplantation (HSCT) has been used as curative treatment in both children and adults for hematologic ... Graft-versus-host disease Stem cell transplantation Skin cancer Squamous cell cancer Basal cell cancer Melanoma Autoimmune ... Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiat Res. 2009;171(2):155-63. ... Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an ...
The preparative or conditioning regimen is a critical element in the hematopoietic cell transplant procedure. The purpose of ... Hematopoietic cell transplantation for aplastic anemia in adults. *Hematopoietic cell transplantation for idiopathic severe ... Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics). *Autologous hematopoietic cell ... Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative ...
NICEs guidance on pancreatic islet cell transplantation has now been replaced. Please go to NICE interventional procedure ... Pancreatic islet cell transplantation. Interventional procedures guidance [IPG13]. Published date: 17 February 2003. ... NICEs guidance on pancreatic islet cell transplantation has now been replaced.. Please go to NICE interventional procedure ... guidance 257 to view the full guidance on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus and to ...
A combination of drugs increases the number of blood stem cells released by bone marrow into circulation and could help ... Improving Blood Stem Cell Transplantation. Research Update March 13, 2013. A recent study conducted in mice, baboons, and human ... Meloxicam in combination with G-CSF may improve the success rates of blood stem cell transplantation by making it easier to ... This finding sheds light on how the body responds to injury and has implications for blood cell transplantation. The ...
Stem Cell Transplantation in minutes with SmartDraw. SmartDraw includes 1000s of professional healthcare and anatomy chart ... Stem Cell Transplantation. donor. stem cells from. peripheral blood. Allogeneic stem cell transplantation. Stem Cell come form ... Bone marrow transplantation. Umbilical cord blood transplantation. Autologous stem cell transplantation. Syngeneic stem cell ... Leukemia - Stem Cell Transplantation. Create healthcare diagrams like this example called Leukemia - Stem Cell Transplantation ...
Early trial results show autologous hematopoietic stem cell transplantation has helped patients with multiple sclerosis walk ... Could stem cell transplantation yield a cure for MS?. Written by Honor Whiteman. on January 27, 2016 ... In the documentary, she revealed how she started to see amazing results within days of undergoing stem cell transplantation. ... The groundbreaking treatment being trialed is called autologous hematopoietic stem cell transplantation (AHSCT) - a procedure ...
See The approach to hematopoietic cell transplantation survivorship and Malignancy after hematopoietic cell transplantation ... Preparative regimens for hematopoietic cell transplantation. *Thalassemia: Management after hematopoietic cell transplantation ... and Thalassemia: Management after hematopoietic cell transplantation and Hematopoietic cell transplantation for aplastic ... Hematopoietic cell transplantation for aplastic anemia in adults. *Hematopoietic support after hematopoietic cell ...
Service has opened a new laboratory in Edinburgh to offer around 12 people a year islet cell transplant therapy.Islet cell ... Islet cell transplantation. A small number of people with Type 1 diabetes can benefit from islet transplantation, a procedure ... "Islet cell transplantation can be life-changing for a small number of people with Type 1 diabetes and getting it to this stage ... Islets are groups of cells in the pancreas that contain the insulin-producing beta cells. In people with Type 1 diabetes, the ...
Studies have shown that stem cell transplantation could aid in the restoration of brain function in patients with medical ... Optimizing stem cell transplantation. BioPhotonics. Aug 2007 Researchers use labeling technique and MRI to track cells in vivo ... Still, they showed they could detect clusters of cells up to 18 weeks after transplantation, assuming that cells retain their ... However, concentrations of cells are high in vitro. The density of cells drops considerably when the cells begin to migrate and ...
Its important to weigh the risks and benefits of stem cell transplantation with your doctor as you consider your treatment ... Allogeneic stem cell transplantation (infusion of donor stem cells into a patient) is the best-documented curative treatment ... Allogeneic Stem Cell Transplantation. *Download or order The Leukemia & Lymphoma Societys free booklet, Blood and Marrow Stem ... On the one hand, transplantation has a proven curative track record for some CML patients. On the other hand, the TKIs may be ...
In bone marrow transplantation for patients weighing,60 kg, it is possible to obtain adequate nucleated cell count by ... Edited and published by : The Japan Society for Hematopoietic Stem Cell Transplantation Produced and listed by : The Japan ... of patients after allogeneic hematopoietic cell transplantation and is the leading cause of late morbidity, mortality and ... A current definition of gene therapy is the infusion of a therapeutic gene, or cells transduced with the gene, in order to cure ...
Two studies published in the current issue of Cell Transplantation (19:12) investigate frontiers of islet cell transplantation ... Retrieving and preserving islet cells taken from nonliving donors for the purpose of islet cell transplantation to regenerate ... Rodolfo Alejandro, section editor for CELL TRANSPLANTATION and Professor of Medicine at the University of Miami Miller School ... "BM-derived cells have been found to differentiate into endothelial cells and their presence has been accompanied by a ...
Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to your body after ... Patients Disease Information Treatment Types of Treatment Stem Cell Transplantation Allogeneic Stem Cell Transplantation ... white cells and platelets. The white cells and platelets, which contain the stem cells, are collected, while the red cells and ... Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to your body after ...
Meerim Park and Jong Jin Seo, "Role of HLA in Hematopoietic Stem Cell Transplantation," Bone Marrow Research, vol. 2012, ... Role of HLA in Hematopoietic Stem Cell Transplantation. Meerim Park1 and Jong Jin Seo2 ...
Fill in any or all of the fields below. Click on the label to the left of each search field for more information or read the Help ...
H. J. Pegram, D. S. Ritchie, M. J. Smyth et al., "Alloreactive natural killer cells in hematopoietic stem cell transplantation ... "The role of anti-HLA antibodies in hematopoietic stem cell transplantation," Biology of Blood and Marrow Transplantation, vol. ... M. Park, K. N. Koh, B. E. Kim et al., "The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in ... D. Gallardo, S. Brunet, A. Torres et al., "HLA-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation ...
... To Reflect Significant Incremental Opportunity During 2018-2026 By ... Application of Stem Cells in Cell Therapy 3.1 Stem Cells Ability to Differentiate 3.1.1 Totipotent Stem Cells 3.1.2 Pluripotent ... Cell Science 2017 It takes us immense pleasure to announce the conference that "Annual Congress on Cell Science, Stem Cell ... Cell Science 2017 conference will focus on the latest and exciting innovations in all areas of Cell Biologists and Stem Cell ...
... studies try to explain how using magnetic particles is beneficial in improving the targeted delivery of transplanted stem cells ... "Because the efficiency of intracoronary stem cell transplantation is limited by low cell retention, we sought to improve cell ... To date, the transplantation of mensenchymal stem cells to the damaged retina has had "limited success" because the cells ... delivery of transplanted stem cells and also improve cell retention have been published in the journal Cell Transplantation. ...
We used an ex vivo hematopoietic stem and progenitor cell/EC (HSPC/EC) coculture system as well as in vivo EC infusions ... Here, we determined that aging of endothelial cells (ECs), a critical component of the BM microenvironment, was sufficient to ... Age-related changes in the hematopoietic compartment are primarily attributed to cell-intrinsic alterations in hematopoietic ... stem cells (HSCs); however, the contribution of the aged microenvironment has not been adequately evaluated. Understanding the ...
Stem-cell based therapies to strengthen the heart muscle and treat other diseases are beginning to show promise in human ... Experimental noninvasive tool assesses efficacy of stem cell transplantation. *Download PDF Copy ... Tags: Biopsy, Blood, Blood Test, Cancer, Cardiac Surgery, Cardiology, Cell, Cell Biology, Children, Childrens Health, Diabetes ... The researchers found circulating exosomes delivered cell components to the target heart muscle cells, resulting in cardiac ...
Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal ... Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy Brain. 2015 Oct; ... Allogeneic haematopoietic stem cell transplantation should be considered for selected patients with an optimal donor. ... Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal ...
Researchers analyzed biomarkers secreted from transplanted human stem cells in the recipient blood of a rodent model of heart ... Experimental Noninvasive Tool Monitors Effectiveness of Stem Cell Transplantation. University of Maryland School of Medicine ... All Journal News Cardiovascular Health Cell Biology Heart Disease Stem Cells Embargoed Feed - hidden ... The researchers found circulating exosomes delivered cell components to the target heart muscle cells, resulting in cardiac ...
... autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple ... Who is most suited to undergo ASCT? Is there an age threshold that should not be surpassed? Should transplantation be embarked ... What is the role of tandem transplantation in the era of novel agents and where do patient-specific cytogenetics come into the ... The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia ...
  • The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood cell production. (
  • For the journal abbreviated Bone Marrow Transplant , see Bone Marrow Transplantation (journal) . (
  • The Worldwide Network for Blood and Marrow Transplantation reported the millionth transplant to have been undertaken in December 2012. (
  • Current research in Stem Cell Transplantation (SCT) focuses on improving transplant outcome through immune manipulations using cell therapy and lymphocyte growth factors. (
  • Nonmelanoma skin cancer in childhood after hematopoietic stem cell transplant: a report of 4 cases. (
  • The preparative or conditioning regimen is a critical element in the hematopoietic cell transplant procedure. (
  • Meloxicam in combination with G-CSF may improve the success rates of blood stem cell transplantation by making it easier to obtain sufficient numbers of cells for transplant. (
  • The Scottish National Blood Transfusion Service has opened a new laboratory in Edinburgh to offer around 12 people a year islet cell transplant therapy. (
  • Islet cell transplant therapy is a pioneering treatment for diabetes that was part-funded by Diabetes UK in its research stages. (
  • The second edition is fully revised and includes new chapters on microbiome, metabolism, kinase targets, micro-RNA and mRNA regulatory mechanisms, signaling pathways in GVHD, innate lymphoid system development, recovery and function in GVHD, genetically engineered T-cell therapies, immune system engagers for GVHD and graft-versus-tumor, and hematopoietic cell transplant for tolerance induction in solid organ grafts. (
  • Cell Transplant. (
  • The immune reaction, or GVHD, is treated by administering drugs to the patient after the transplant that reduce the ability of the donated immune cells to attack and injure the patient's tissues. (
  • One goal of allogeneic stem cell transplant is to cause the T lymphocytes in the donor's blood or marrow to take hold (engraft) and grow in the patient's marrow. (
  • The technique involves treating the stem cells collected for transplant with agents that reduce the number of T lymphocytes. (
  • If the HLA on the donor cells are identical (from identical twins, for example) or similar (such as those from siblings), the transplant is more likely to be successful. (
  • 12 12 Stem Cell Transplant and Cellular Therapy Unit, University Hospital, Siena, Italy. (
  • Lucy Godley, MD, PhD, talks about what stem cell transplants are like for the patient receiving the transplant, potential complications associated with the procedure, and the long-term prognosis after transplant. (
  • Please call our Physician Referral Center at (800) 995-5724 to refer a patient to the Stem Cell Transplant program. (
  • Over the past 2 decades, different strategies including profound T-cell depletion and post-transplant immunosuppression were attempted to overcome these limitations without major success. (
  • With the implementation of post-transplant cyclophosphamide (PtCy), haploidentical transplantation has become a safe and viable option for many patients in need of a donor. (
  • In addition, we are planning to use this platform to answer fundamental research questions in transplant tolerance and to improve GVHD prevention after haploidentical transplantation. (
  • In summary, haploidentical transplantation has emerged as a safe and effective transplant alternative that addresses several shortcoming of sibling and unrelated donor transplant and has open a new era in bone marrow transplantation for hematologic disorders. (
  • Because stem cell transplant is so dramatically different in prevention in terms of its intensity, in terms of its expanse, and in terms of its treatment-related mortality, that is very informative. (
  • This research achievement is expected to enhance the treatment safety and efficiency of degenerative neural disorders as it can precisely transplant the exact amount of stem cell-based treatment cells to human body tissues and organs. (
  • Stem cell treatment has been taking limelight as a regenerative medical technique for intractable disorder treatment, but it cannot transplant the exact amount of stem cells to the target areas in need of treatment deeply inside body or may carry injection risk. (
  • Scientists at VCU Massey Cancer Center's award-winning Bone Marrow Transplant (BMT) Program believe it is, and they recently published several studies that support the possibility of using next-generation DNA sequencing and mathematical modeling to not only understand the variability observed in clinical outcomes of stem cell transplantation, but also to provide a theoretical framework to make transplantation a possibility for more patients who do not have a related donor. (
  • Despite efforts to match patients with genetically similar donors, it is still nearly impossible to predict whether a stem cell transplant recipient will develop potentially fatal graft-versus-host disease (GVHD), a condition where the donor's immune system attacks the recipient's body. (
  • This is called a stem-cell transplant. (
  • stem cell transplantation : Autologous Hematopoietic Stem Cell Transplantation will be performed on all participants randomized to transplant arm. (
  • Stem cell transplant (also known as bone marrow transplant or BMT) is an established treatment for many cancers and blood diseases once considered incurable. (
  • Ongoing advances in stem cell transplant are expanding its availability and improving outcomes for patients, young and old. (
  • Here at the University of Chicago Medicine, the brightest minds in medicine are ready to meet the needs of all patients considering a stem cell transplant. (
  • We offer the latest promising approaches in blood and bone marrow stem cell transplant. (
  • Recognizing the distinct needs of this population, we've assembled a multidisciplinary team of stem cell transplant and geriatric oncology experts to design a care program tailored specifically for patients over 60. (
  • The Stem Cell Transplant Unit, located on the top floor of the Center for Care and Discovery, offers the newest technology as well as many thoughtful patient and family amenities. (
  • The unit integrates both inpatient and outpatient stem cell transplant care services in one convenient location. (
  • For information about stem cell transplant for children and teens, visit the Pediatric Stem Cell Transplant page on the University of Chicago Comer Children's Hospital website. (
  • The patients were evaluated while on the transplant waiting list, and at selected intervals after islet cell transplantation. (
  • These were criteria to take part in the study, and to undergo an islet cell transplant, because the benefit of good glycemic control must outweigh the risk of chronic immunosuppression. (
  • The Diabetes Research Institute is one of only five centers worldwide to receive funding from the National Institutes of Health for clinical islet cell transplant trials. (
  • transplant procedure for treating mastocytosis-a disease of abnormal mast cell growth. (
  • This study will examine whether a stem cell transplant from a healthy donor can similarly target and destroy mast cells in a "graft-versus-mast cell" effect. (
  • This line will remain in place throughout the transplant and recovery period and will be used to transfuse blood components, administer medicines, infuse the donated stem cells, and draw blood for tests. (
  • Patients will begin conditioning with cyclophosphamide, starting 7 days before the transplant, and fludarabine, starting 5 days before the transplant, to prevent rejection of the donated cells. (
  • In this protocol, we propose to treat patients with advanced forms of mastocytosis with an allogeneic stem cell transplant from an HLA-identical sibling, using a low intensity non-myeloablative regimen. (
  • This approach has the advantage of decreasing the transplant-related toxicity while allowing adequate immunosuppression to establish stem cell and lymphocyte engraftment. (
  • Below is a brief overview of the stem cell transplant process. (
  • Shortly before your child's stem cell transplant, your child will undergo chemotherapy and/or radiation. (
  • 12 It is the care of the patient after transplantation that can present much more of a challenge to the multidisciplinary care team, especially in the setting of allogeneic transplant. (
  • In this article we aim to familiarize primary care practitioners with some of the basics of allogeneic and autologous transplantation, as well as issues relevant to the care of transplant recipients over the short and the long term. (
  • Juliet Barker, Director of Memorial Sloan Kettering's Cord Blood Transplant Program, discusses MSK's expertise in cord blood transplantation. (
  • A. M. JAMES SHAPIRO is Professor of Surgery, Division of General Surgery, University of Alberta, Canada, and Director of Clinical Islet Transplant Program, Staff Surgeon, and Director of the Juvenile Diabetes Foundation Clinical Center for Islet Transplantation, University of Alberta Hospital, Canada. (
  • Because the defect is present in every cell of the body, we did not expect a bone marrow stem cell transplant to be so widespread and effective," says Cherqui. (
  • However, it is not clear that stem cells found in bone marrow are required in order to render a transplant candidate immunologically tolerant. (
  • For instance, if an individual with IPEX has diabetes before transplant, they will still have diabetes after transplant, because the cells in the pancreas that make insulin have been destroyed by this disease, and HSCT cannot replace pancreatic cells. (
  • The transplant itself does not require surgery for the recipient, as the hematopoietic stem cells are typically infused into a large vein in the same way that a patient receives a blood transfusion. (
  • Two days after finishing chemotherapy, you will receive a transplant of stem cells from a sibling. (
  • JSHCT has been primarily the academic society for transplant clinicians but recently it is expanding its interests to cell therapy and regenerative medicine. (
  • The core activities of JSHCT are consisted of organizing annual congress, publishing quarterly JSHCT Letters, managing the data centres for transplant patient and donor registration, publishing Annual Report of Nationwide Survey for transplant recipients, promoting more than 20 working groups, steering more than 10 committees and publishing multiple guidelines for hematopoietic stem cell transplantation. (
  • The JDCHCT performs data collection, data management, and statistical analyses to promote clinical research in HSCT.HSCT recipient-, donor- and outcome- data are collected by using Transplant Registry Unified Management Program (TRUMP) in collaboration with Japan Society for Hematopoietic Cell Transplantation, Japan Society for Paediatric Hematology and Oncology, Japan Marrow Donor Program, Cord Blood Banks and Japanese Red Cross Society. (
  • The JDCHCT also collaborates with international related organizations including Worldwide Network for Blood and Marrow Transplantation, Asia-Pacific Blood and Marrow Transplantation Group, Center for International Blood and Marrow Transplant Research, and European Group for Blood and Marrow Transplantation. (
  • JSHCT played a central role in developing the 'Transplant Registry Unified Management Program (TRUMP)' to enable transplantation institutes to manage patient information with emphases on convenience to institutes, safety of patient information, and quality of data management. (
  • Hematopoietic cell transplant (HCT) is increasingly used as a treatment for various malignant and non-malignant disease processes. (
  • To evaluate a group of 106 patients with Hodgkin's lymphoma, who suffered relapse or who were refractory to treatment, submitted to autologous hematopoietic stem cell transplantation in a single transplant center. (
  • Autologous hematopoietic stem cell transplantation is an effective treatment strategy for early and late relapse in classical Hodgkin's lymphoma for cases that were responsive to pre-transplant chemotherapy. (
  • An unusual autoimmune disease that causes skin and lung damage can be treated effectively by stem cell transplant, a new study in the New England Journal of Medicine has found. (
  • The history of stem cell transplant goes back as early as 1939, when the first documented clinical transplant was performed. (
  • In 1968, the first successful allogenic stem cell transplant was made possible followed by series of achievements in 1970s and 1980s. (
  • Donor lymphocyte infusion (DLI) has a significant role in relapsed patients with chronic myelogenous leukemia (CML) after stem cell transplant. (
  • The success of collection of mobilized stem cells from peripheral blood was a milestone in the history of transplant. (
  • He has an HLA-matched related donor (his brother) who agrees to donate hematopoietic cells for an allogeneic transplant. (
  • Stem cell transplant (Step 1). (
  • If the transplant is successful, new bone marrow cells will produce healthy red blood cells, white blood cells, and platelets. (
  • In order for the transplant to be successful, certain markers on the blood cells and bone marrow cells must match. (
  • Sarah McInerney (40) has obtained chemotherapy and a stem cell transplant, which is not available in Ireland to treat progressive Multiple Sclerosis. (
  • If the cells are not from a genetically identical donor the person's body will recognize them as foreign and the immune system will begin to attack them as with any transplant rejection. (
  • Hematopoietic stem cell transplantation ( HSCT ) is the transplantation of multipotent hematopoietic stem cells , usually derived from bone marrow, peripheral blood, or umbilical cord blood. (
  • Autologous HSCT requires the extraction ( apheresis ) of haematopoietic stem cells (HSC) from the patient and storage of the harvested cells in a freezer. (
  • The spectrum of target antigens associated with tumor immunity and alloimmunity after allogeneic HSCT: Host-derived T and B cells can be induced to recognize tumor-associated antigens, whereas donor-derived B and T cells can recognize both tumor-associated antigens and alloantigens. (
  • It is important to note, however, that while the United States Food and Drug Administration (FDA) have approved hematopoietic stem cell transplantation (HSCT) for use against cancer , it is not yet approved for wider use. (
  • Allogeneic HSCT requires a donor to supply suitable stem cells. (
  • Autologous HSCT avoids the issue of trying to find a matching donor because stem cells are harvested from the patients themselves. (
  • Hematopoietic stem cell transplantation (HSCT) has been used as curative treatment in both children and adults for hematologic malignancies, immunodeficiencies, autoimmune disorders, and other rare indications. (
  • In this chapter, we discuss indications for HSCT, conditioning regimens before transplantation, and types of HSCTs. (
  • Increasing rate of incidence is in turn, expected to increase the demand for hematopoietic stem cell transplantation thus, propelling growth of the hematopoietic stem cell transplantation (HSCT) market. (
  • A collaborative research study on hematopoietic stem cell transplantation initiated by World Network for Blood and Marrow Transplantation (WBMN) in 2013 in the domain of promotion of access to hematopoietic stem cell transplantation, developed a donation guidance document, technical and scientific input on safety, and quality of HSCT as mentioned in annual report of the WBMN. (
  • Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the management of AML with GS. (
  • These data suggest that better control of GS prior to allo-HSCT is crucial to improve the outcome of transplantation for those with GS. (
  • However, the optimal therapeutic strategy for GS remains unclear, especially in regards to the indications for need of allogeneic hematopoietic stem cell transplantation (allo-HSCT). (
  • This study included all consecutive adult AML aged over 15 years, excluding patients with acute promyelocytic leukemia, who underwent allo-HSCT for the first time between January 2000 and December 2008 at the nine institutions participating in the Kanto Study Group for Cell Therapy. (
  • An HLA-matched singling is the ideal donor for allogeneic hematopoietic stem cell transplantation (HSCT), but such a donor is available for less than 30% of patients who require allogeneic HSCT. (
  • Therefore, HLA-matched unrelated HSCT, HLAmismatched related HSCT, and unrelated cord blood transplantation have been investigated. (
  • One-antigen mismatched related HSCT can be performed without T-cell depletion, but the outcome has been somewhat inferior to HSCT from an HLA-matched sibling or HSCT from an HLA-allele-matched unrelated donor. (
  • Two- or three-antigen mismatched related HSCT without ex vivo T-cell depletion has been investigated in Japan using a variety of strategies including in vivo T-cell depletion using anti-thymocyte globulin or alemtuzumab, and its safety has become close to that of HLA-matched HSCT. (
  • However, the appropriate choice of these strategies as well as the difference in HSCT outcome with cord blood transplantation has not been clarified. (
  • Autologous HSCT is performed using the patient's own hematopoietic stem cells, which are harvested before transplantation and reinfused after myeloablation. (
  • Allogeneic HSCT uses human leukocyte antigen (HLA)-matched stem cells derived from a donor. (
  • This article reviews the biology of stem cells, clinical efficacy of HSCT, transplantation procedures, and potential complications. (
  • Cytomegalovirus (CMV) infection remains a significant complication after hematopoietic stem cell transplantation (HSCT) and may have a deleterious impact on the overall outcome after transplantation. (
  • When PI is likely to cause significant harm or death to someone, allogeneic hematopoietic stem cell transplantation (HSCT) may be the best treatment option. (
  • The person who receives the stem cells is called a recipient of HSCT. (
  • If an allogeneic HSCT is successful, the donor's hematopoietic stem cells will replace the recipient's own cells. (
  • An allogeneic HSCT can replace an individual's own hematopoietic stem cells with stem cells that will produce normal immune system cells. (
  • Allogeneic HSCT also fixes any problems with other blood cells. (
  • Hematopoietic stem cells may be collected from the bone marrow, the peripheral blood, or from umbilical cord blood, so HSCT procedures may be called bone marrow transplants, peripheral blood stem cell transplants, or cord blood transplants depending on the source of the stem cells. (
  • Histocompatible hematopoietic stem cell transplantation (HSCT) was conducted on a 4.5-year-old girl with Niemann-Pick disease type B. The donor was her unaffected brother. (
  • 4.8 If haematopoietic stem cell transplantation (HSCT) is urgent and there are no suitable available donors, assess risk and liaise with the registry. (
  • Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT) collects and analyses recipient-, donor-, and outcome- information of the hematopoietic stem cell transplantation (HSCT) in Japan. (
  • Hematopoietic stem cell transplantation (HSCT) is the replacement of a diseased or deficient bone marrow by normal cells, with the aim of reconstituting the marrow and providing immune system control. (
  • To provide an overview of recently published work on autologous hematopoietic stem-cell transplantation (HSCT) in patients with systemic sclerosis (SSc). (
  • HSCT involves the intravenous (IV) infusion of autologous or allogeneic stem cells to re-establish hematopoietic function in patients whose bone marrow or immune system is damaged or defective. (
  • Transplantation of HSC (HSCT) is done in order to re-establish bone marrow and immune system function after being damaged and/or attacked by blood cancer. (
  • The most common indications for HSCT are blood cancers, mainly acute leukaemia, cancers of the lymphatic tissues (lymphomas) and the antibody-forming blood cells (multiple myeloma). (
  • HSCT can be broadly divided into autologous transplantation, where patients use their own blood stem cells, and allogeneic transplantation, where stem cells are obtained from a different person. (
  • Other conditions [13] treated with stem cell transplants include sickle-cell disease , myelodysplastic syndrome , neuroblastoma , lymphoma , Ewing's sarcoma , desmoplastic small round cell tumor , chronic granulomatous disease , Hodgkin's disease and Wiskott-Aldrich syndrome . (
  • In 2006 a total of 50,417 first hematopoietic stem cell transplants were reported as taking place worldwide, according to a global survey of 1327 centers in 71 countries conducted by the Worldwide Network for Blood and Marrow Transplantation. (
  • What are stem cell transplants used to treat? (
  • Stem cell transplants are approved to treat various cancers. (
  • To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. (
  • Allogeneic stem cell transplants for patients who are older or have overall poor health are relatively uncommon. (
  • However, reduced intensity allogeneic stem cell transplants may be an appropriate treatment for some older or sicker patients. (
  • We perform both autologous (your own) and allogenic (from a related or unrelated donor) stem cell transplants at King's College Hospital. (
  • Other conditions treated with stem cell transplants include sickle-cell disease , myelodysplastic syndrome , neuroblastoma , lymphoma , Ewing's Sarcoma , Desmoplastic small round cell tumor , Hodgkin's disease , and multiple myeloma . (
  • Allogeneic transplants are also performed using umbilical cord blood as the source of stem cells. (
  • Options for individuals lacking a related donor include haplo-cord transplants -- a combination of donated umbilical cord blood stem cells and half-matched (haploidentical) cells from a related donor. (
  • Recipients of stem cell transplants may be severely immunocompromised for many months after transplantation, especially if they are still taking immunosuppressive drugs. (
  • Allogeneic transplantation represents 40% of all stem cell transplants performed annually in Canada and requires donor and recipient matching for major histocompatibility (HLA) antigens. (
  • A clinical trial at MSK has shown that fecal transplants are safe in people who have had stem cell or bone marrow transplants. (
  • The importance of this effect was demonstrated by an increased rate of leukemia relapse in patients receiving transplants in which identical twin donors were used or T cell depletion of donor marrow was performed ( 5 ). (
  • However, in contrast to the 100% donor hematopoietic engraftment typical of myeloablative transplantation, such nonmyeloablative transplants typically resulted in a state of mixed hematopoietic chimerism. (
  • Bone marrow is the traditional source of stem cells for both autologous and homologous transplants. (
  • In the case of transplants using HSC derived from other people, the conditioning therapy also helps reduce the risk of the recipient's body killing or rejecting the incoming donor stem cells (graft rejection). (
  • Another type of HSC source is cord blood cells that are used in umbilical cord blood transplants. (
  • [2] In these cases, the recipient's immune system is usually destroyed with radiation or chemotherapy before the transplantation. (
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (
  • The cells are cleaned and frozen before being reintroduced to the individual after they receive the chemotherapy drugs. (
  • When used to treat cancers such as non-Hodgkin's lymphoma and multiple myeloma, high-dose chemotherapy also destroys normal cells such as the HSCs and HPCs in the bone marrow. (
  • To replenish the lost cells, HSCs and HPCs are routinely harvested from a donor's or patient's blood, and then transplanted back into the patient at the conclusion of the chemotherapy procedure to repopulate the bone marrow. (
  • Next, the patient will undergo high-dose chemotherapy in order to destroy and clear all the harmful immune cells that are attacking the brain and spinal cord. (
  • Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to your body after high-intensity chemotherapy or radiation. (
  • The high-conditioning regimens are meant to severely or completely impair your ability to make stem cells and you will likely experience side effects during the days you receive high-dose conditioning radiation or chemotherapy. (
  • 9 GS was defined as extramedullary tumors that were identified at any time from the diagnosis to transplantation by physical examination and/or imaging studies (computed tomography scan and/or magnetic resonance imaging) and that responded to chemotherapy or irradiation. (
  • After autologous peripheral blood stem cells were collected, she underwent autologous peripheral blood stem cell transplantation by conditioning with high-dose melphalan chemotherapy. (
  • We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. (
  • As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation. (
  • Fellows will develop the clinical skills and understanding necessary to become a outstanding provider of care for patients with diseases requiring high-dose chemotherapy and hematopoietic stem cell transplantation. (
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy in the form of total body irradiation to eradicate the patient's malignant cell population at the cost of also eliminating the patient's bone marrow stem cells, then return of the patient's own stored stem cells to their body. (
  • Patients first receive intensive chemotherapy and radiation to rid the body of cancer cells. (
  • From 1 to 3 days after the chemotherapy is completed, the stem cells will be transfused through the central venous line. (
  • Intrahippocampal transplantation of human neural stem cells resolved all cognitive impairments when animals were tested 1 month after the cessation of chemotherapy. (
  • Granule and pyramidal cell neurons within the dentate gyrus and CA1 subfields of the hippocampus exhibited significant reductions in dendritic complexity, spine density, and immature and mature spine types following chemotherapy, adverse effects that were eradicated by stem cell transplantation. (
  • After completion of chemotherapy, you will receive TBI, and later on the same day, blood stem cells from a donor will be given through the catheter. (
  • There is growing evidence that relapses may be explained not only by resistance to chemotherapy but also by the escape of tumor cells from the control of the allogeneic immune response. (
  • Patients undergoing hematopoietic stem cell transplantation receive high doses of chemotherapy and radiotherapy, which cause severe immunosuppression. (
  • The study evaluates the effect of inactivation of the immune system with chemotherapy and immunotherapy and infusion of bone marrow stem cells in early onset type 1 diabetes mellitus. (
  • Because even high doses of irradiation or chemotherapy cannot eradicate all malignant cells in all patients, ever more intensive conditioning regimens dominated efforts in clinical marrow transplantation until the late 1990s. (
  • In contrast to traditional allogeneic stem cell transplantation, in which the patient receives myeloablative conditioning (chemotherapy and/or irradiation), in NST, if donor cells are not infused or are rejected, the recipient's own bone marrow usually recovers spontaneously. (
  • The patient receives chemotherapy to kill blood-forming cells. (
  • The rationale underlying autologous transplantation is to deliver high doses of chemotherapy (with or without radiotherapy). (
  • Haematopoietic stem cell transplantation has been proposed as treatment for mitochondrial neurogastrointestinal encephalomyopathy, a rare fatal autosomal recessive disease due to TYMP mutations that result in thymidine phosphorylase deficiency. (
  • We conducted a retrospective analysis of all known patients suffering from mitochondrial neurogastrointestinal encephalomyopathy who underwent allogeneic haematopoietic stem cell transplantation between 2005 and 2011. (
  • Twenty-four patients, 11 males and 13 females, median age 25 years (range 10-41 years) treated with haematopoietic stem cell transplantation from related (n = 9) or unrelated donors (n = 15) in 15 institutions worldwide were analysed for outcome and its associated factors. (
  • Through studies on mice, they found allogeneic haematopoietic stem cell transplantation can lead to a significant reduction in a type of epithelial cell in the colon's inner lining called a goblet cell. (
  • Dr Colin Phipps Diong, Parkway Cancer Centre's new consultant specialising in lymphoma and blood cancers, and haematopoietic stem cell transplantation, explains haematopoietic stem cell transplantation. (
  • The term haematopoietic stem cell (HSC) refers to cells made in the blood factory or bone marrow that have the potential to grow into almost any type of blood cell. (
  • As well as using stem cells from a donor's blood, cells from umbilical cord blood can also be used. (
  • Umbilical cord blood stem cells are frozen at birth, which is important because they do not suffer any environmental damage or aging. (
  • Umbilical cord blood transplantation is associated with increased risk of HHV-6 encephalitis. (
  • Hematopoietic cell transplantation (HCT) from HLA identical related or unrelated donors or from umbilical cord blood units can cure malignant and non-malignant hematologic, immune and metabolic disorders. (
  • Comparisons with sibling, unrelated and umbilical cord blood transplantation have shown at least comparable outcomes, with low incidence of GVHD and non-relapse mortality. (
  • Umbilical cord blood transplantation has been increasingly used over the past years for both malignant and non-malignant hematologic and other diseases as an alternative to mismatched-related or matched-unrelated bone marrow or peripheral blood hematopoietic stem cell transplantation. (
  • Umbilical cord blood is an alternative hematopoietic stem cell source that can cause various diseases through transplantation. (
  • In 2014, according to the World Marrow Donor Association (WMDA), stem cell products provided for unrelated transplantation worldwide had increased to 20,604 (4,149 bone marrow donations, 12,506 peripheral blood stem cell donations, and 3,949 cord blood units). (
  • It may be a useful strategy that we select donors with high level of platelet count or who can provide their peripheral blood stem cell. (
  • We will further expand this experience using both, myeloablative and reduced intensity conditioning and peripheral blood stem cell grafts to allow our patients to have a safe and comprehensive approach that will be applicable within a large range of age and comorbidities. (
  • 17. The method of claim 1, wherein the hematopoietic system reconstituting cells administered to the recipient are present in a source population of between 1.0 10 8 and 40 10 8 donor cytokine mobilized peripheral blood stem cells/kg of recipient's body weight. (
  • With the availability of the stem cell growth factors GM-CSF and G-CSF, most hematopoietic stem cell transplantation procedures are now performed using stem cells collected from the peripheral blood, rather than from the bone marrow. (
  • Stem cell source was bone marrow (n = 11) and peripheral blood (n = 16). (
  • Although stem cells can be collected by direct aspiration from the bone marrow, with the patient under general or spinal anesthetic ( Fig. 1 ), they are now more commonly harvested from the peripheral blood. (
  • Blood stem cell transplantation is accomplished by treating the donor with hematopoietic growth factors, which cause the stem cells to proliferate and circulate freely in the peripheral blood. (
  • The cells will be recollected from peripheral blood by apheresis and refrigerated. (
  • Lack of persistent remission following initial recovery in patients with type 1 diabetes treated with autologous peripheral blood stem cell transplantation. (
  • To assess metabolic control in patients with newly diagnosed type 1 diabetes mellitus who underwent immunoablation followed by autologous peripheral blood stem cell transplantation (APBSCT) as a treat. (
  • Pilot studies of autologous stem cell transplantation using peripheral blood have demonstrated rapid engraftment with this technique. (
  • However, because of higher number of T cells infused in cases of peripheral blood as a source, the incidence of chronic GVHD is higher. (
  • The more common way is to collect them from the blood stream, or "peripheral blood stem cell harvesting. (
  • The groundbreaking treatment being trialed is called autologous hematopoietic stem cell transplantation (AHSCT) - a procedure that is currently used to treat cancers of the bone and blood, such as leukemia and multiple myeloma . (
  • More than 30 years after its introduction, autologous stem cell transplantation (ASCT) remains the standard of care for young patients with newly diagnosed multiple myeloma. (
  • A previous study whereby the median age of patients was 72 years old concluded that elderly multiple myeloma patients should not be excluded from transplantation displaying good results with melphalan 140 mg/m 2 (ref. 16 ). (
  • Single versus double autologous stem-cell transplantation for multiple myeloma. (
  • Tandem bone marrow transplantation in multiple myeloma. (
  • Our patients see physicians who are experts not only in transplantation but also in the patient's specific cancer or blood disease, such as leukemia, lymphoma and multiple myeloma. (
  • He is a member of the Editorial Board of Journal of Transplantation Technologies & Research and reviewer for Blood and Bone Marrow Transplantation, has authored over 100 scientific publications, and has been awarded multiple research grants, including a $5.7M grant from the California Institute of Regenerative Medicine in 2018. (
  • 1 Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. (
  • 3 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Lorry I. Lokey Stem Cell Research Building, 265 Campus Drive, Stanford, CA 94305-5461, USA. (
  • The researchers concluded that DPaSCs could provide a source of stem cells for tooth regeneration and repair as well as a wide range of regenerative medicine applications in humans. (
  • Cell Transplantation is a monthly peer-reviewed medical journal covering regenerative medicine. (
  • Please go to NICE interventional procedure guidance 257 to view the full guidance on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus and to NICE interventional procedure guidance 274 to view the full guidance on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy issued to the NHS in England, Wales, Scotland and Northern Ireland. (
  • Patients contemplating hematopoietic cell transplantation (HCT), like any other major medical intervention, often question what the quality of their lives will be following the procedure. (
  • A small number of people with Type 1 diabetes can benefit from islet transplantation, a procedure in which an individual's destroyed islet cells are replaced using cells harvested from donor pancreases. (
  • Allogeneic stem cell transplantation can be a high-risk procedure. (
  • Given the rapidly rising healthcare costs, it is important to understand the economic costs of hematopoietic cell transplantation (HCT), a procedure that is being used more frequently in the treatment of various hematologic disorders. (
  • Studies have reported a wide range of costs for HCT, from $36 000 to $88 000 (USD) for a single autologous transplantation for the initial hospitalization, to $200 000 (USD) or more for a myeloablative allogeneic procedure involving an unrelated donor. (
  • Bone marrow transplantation (or stem cell transplantation) is a well-established procedure for patients with relapsed or high-risk cancers of the blood, such as leukaemia , lymphoma and myeloma . (
  • Stem cell transplantation is a medical procedure in the fields of hematology and oncology , most often performed for people with diseases of the blood , bone marrow , or certain types of cancer . (
  • Islet cell transplantation is a groundbreaking procedure that is considered the most promising method for curing diabetes. (
  • During the procedure islet cells are separated from a donor pancreas, and infused into a patient's liver, where they begin to produce insulin. (
  • Also, from 4 days before the transplantation until about 3 months after the procedure, patients will receive cyclosporine and mycophenolate mofetil-drugs that help prevent both rejection of the donated cells and attack by the donor cells on the patient's cells (called graft-versus-host disease). (
  • Our physicians have been at the forefront of advances in hematopoietic (blood-forming) stem cell transplantation since the procedure was developed decades ago. (
  • The procedure virtually halted the cystine accumulation responsible for the disease, and the cascade of cell death that follows. (
  • A procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. (
  • A procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor. (
  • This procedure is done if the stem cells in your bone marrow are not functioning or are deficient. (
  • In this procedure, blood is drawn from one arm, which then goes through a machine that filters out stem cells and white blood cells. (
  • After conditioning therapy, stem cells are infused into the bloodstream (usually between 30 and 60 minutes), akin to a blood transfusion procedure. (
  • Improved control of glycated HbA1c, reduced risk of recurrent hypoglycemia and of diabetic complications are also seen as important benefits of islet cell transplantation, irrespective of the status of insulin independence. (
  • The preferred preparative regimen for specific diseases and the approaches to prevention of the other major complications of hematopoietic cell transplantation (eg, graft-versus-host disease) are discussed separately. (
  • Identify and manage infectious complications of transplantation including suspected and documented bacterial, viral and/or fungal infections. (
  • Manage thrombotic and hemorrhagic complications of transplantation including bleeding, DIC, TTP and deep venous thromboses. (
  • Diagnose and manage other complications of transplantation, including hemorraghic cystitis, diffuse alveolar hemorrhage, veno-occlusive disease and graft failure. (
  • SAN FRANCISCO (GenomeWeb) - A Cornell University research team aims to harness single-cell and cell-free DNA technologies to develop better, noninvasive methods to diagnose complications from kidney transplantation. (
  • Pulmonary complications are common following hematopoietic cell transplantation (HCT) and contribute significantly to its morbidity and mortality. (
  • The use of a short course of cyclophosphamide early after graft infusion targets and rapidly depletes donor and host alloreactive T-cells. (
  • This protocol using busulfan, cyclophosphamide and melphalan has been designed as conditioning therapy for patients receiving stem cell transplantation for acute leukemia or myelodysplastic syndrome (MDS). (
  • Patients treated with therapy plan consisting of Busulfan every 6 hours on days -7 through -4, Cyclophosphamide 60 mg/kg/day IV x 2 days, Melphalan 140 mg/m on day -1, antithymocyte globulin (ATG), G-CSF (granulocyte colony-stimulating factor) and stem cell transplantation on day 0. (
  • Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2. (
  • Stem cell transplantation significantly reduced the number of activated microglia after cyclophosphamide treatment in the brain. (
  • Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may slow or stop their growth and spread throughout the body. (
  • A case is presented of pulmonary Langerhans' cell granulomatosis which recurred following lung transplantation and responded to cyclophosphamide. (
  • We report a case of a young man transplanted for Langerhans' cell granulomatosis in whom there was documented evidence of recurrence of disease in the transplanted lung which responded to treatment with cyclophosphamide. (
  • The patients will receive a nonmyeloablative conditioning regimen with cyclophosphamide and fludarabine, and after this, the cells will be injected intravenously. (
  • The reinfusion of stem cells will be completed after the last dose of cyclophosphamide, through a peripheral vein. (
  • Analysis of risk factors for acute cutaneous graft-versus-host disease after allogeneic stem cell transplantation. (
  • Whole-body UVB irradiation during allogeneic hematopoietic cell transplantation is safe and decreases acute graft-versus-host disease. (
  • Irvine, Calif., July 19, 2006, Transplanting human embryonic stem cells does not cause harm and can be used as a therapeutic strategy for the treatment of acute spinal cord injury, according to a recent study by UC Irvine researchers. (
  • A single case report detailed a possible cure resulting from stem-cell transplantation from a CCR5-delta32 homozygous donor (performed to treat acute myelocytic leukemia). (
  • Newswise - A study published in this month's Anesthesiology highlights the potential of cell-based therapies for the treatment of acute lung injury and acute respiratory distress syndrome (ARDS). (
  • This discovery may represent a milestone in acute lung injury therapy, which is based on removing and then reintroducing cells from the same individual. (
  • These cells were then reintroduced into the circulatory system of the same animal that had undergone induced acute lung injury. (
  • Our results obtained from a rabbit model of acute lung injury showed that transplantation of these premature EPCs significantly improved the function of lung blood vessels, reduced the amount of water that leaked into lungs, and decreased bleeding in the lungs. (
  • Both Dr. Burnham and Dr. Lam, however, emphasized that more animal studies need to be performed before EPC transplantation for acute lung injury can be considered safe for human subjects. (
  • Again, Dr. Burnham: "Although cell-based therapies for lung injury are still a faraway goal, studies such as this by Dr. Lam and his colleagues provide important information that will undoubtedly aid in the development of novel therapies for acute lung injury and ARDS," she said. (
  • Relapse of the original disease is a major cause of death after allogeneic hematopoietic cell transplantation (allo-HCT) for acute leukemias. (
  • However, other than observing clinical outcomes, lack of a repeatable, time-sensitive and noninvasive tool to assess the effectiveness of the transplanted cells within the target organ has slowed progress in the stem cell field. (
  • In the new study, Gao teamed up with colleagues at Shanghai Jiao Tong University, including Jia Li, Yaohui Tang, and Guo-Yuan Yang, to test whether cotransplantation of both neural and vascular precursor cells would lead to better outcomes. (
  • Clinical Outcomes and Future Directions in Islet Transplantation. (
  • Based on the notion that outcomes in human transplantation were unacceptable due to the requirement for long-term pharmacologic immunosuppression, and building on significant preclinical data, investigators at Massachusetts General Hospital attempted to achieve tolerance in humans. (
  • each play an important role in society by reporting the number and outcomes of transplantations and contributing new findings obtained from studies on individual topics. (
  • Curcumin may play a protective role against oxidative stress in islet transplantation outcomes. (
  • 1994) Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. (
  • Marb n, E. Magnetic Enhancement of Cell Retention, Engraftment, and Functional Benefit After Intracoronary Delivery of Cardiac-Derived Stem Cells in a Rat Model of Ischemia/Reperfusion. (
  • 7 The use of blood stem cells is associated with faster recovery of neutrophils and platelets after transplantation (engraftment) than is the case with bone marrow stem cells. (
  • This section describes the 4 components of allogeneic transplantation - conditioning, transplantation, engraftment and immunoreconstitution ( Fig. 2 ) - and provides information about the patient's hospital stay and the risks associated with this type of transplantation. (
  • See 'Preparative regimens for hematopoietic cell transplantation' and 'Hematopoietic support after hematopoietic cell transplantation' and 'Treatment of chronic graft-versus-host disease' . (
  • Islet cell transplantation is an attractive alternative therapy to conventional insulin treatment or vascularized whole pancreas transplantation for type 1 diabetic patients. (
  • It represents a successful example of somatic cell therapy in humans based on complex procedures for islet isolation from whole pancreas. (
  • Islets are groups of cells in the pancreas that contain the insulin-producing beta cells. (
  • BM-derived cells have been found to differentiate into endothelial cells and their presence has been accompanied by a proliferation of recipient pancreatic cells that resulted in increased insulin production in the host pancreas," said corresponding author Dr. Lorenzo Piemonti. (
  • This suggests that there might be a 'cross talk' between bone marrow cells and the pancreas. (
  • Surgically placing the beta (islet) cells from the pancreas of one person into the pancreas of another. (
  • The Surgical Aspects of Pancreas Procurement for Pancreatic Islet Transplantation. (
  • In addition to his clinical interests in insulin pump therapy, pancreas and islet transplantation, his research group are exploring gene therapy for diabetes and beta cell replacement including stem cell approaches. (
  • Islet transplantation is the transplantation of isolated islets from a donor pancreas into another person. (
  • Retrieving and preserving islet cells taken from nonliving donors for the purpose of islet cell transplantation to regenerate islet cells for patients suffering from diabetes is a current and successful practice. (
  • Although transplanting islet cells may one day help people with diabetes, it is still in the research stage. (
  • Sernova Corp., of London, Ontario, is taking islet cell transplantation to the next level by combining transplanted insulin-producing islet cells with its Cell Pouch device in a Phase I/II trial in patients with Type I diabetes. (
  • Increasing awareness about stem cell therapies among the population is also expected to propel growth of the hematopoietic stem cell transplantation market. (
  • Plasticell, which specializes in the development of stem cell technologies and cell-based therapies, announced entering into an agreement with Nan yang Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell pipeline. (
  • Also, GE Healthcare announced the introduction of Thaw CB1000, for thawing large volumes of cell therapies cryopreserved in cryo-bags majorly intended for use in research laboratory, in September 2017. (
  • Stem-cell based therapies to strengthen the heart muscle and treat other diseases are beginning to show promise in human clinical trials. (
  • Derive a thorough understanding of the standards of care in clinical transplantation and the role of experimental therapies for high-risk diseases. (
  • In this manuscript, the team suggests that by inhibiting peptide generation through immunosuppressive therapies in the earliest weeks following stem cell transplantation, antigen presentation to donor T cells could be diminished, which reduces the risk of GVHD as the recipients reconstitute their T-cell repertoire. (
  • It will also explore novel stem cell-based therapies for transplantation in cancer. (
  • Stem cell-based therapies for stroke have expanded substantially over the last decade. (
  • Cell-based therapies have been studied extensively in the context of transplantation tolerance induction. (
  • Cell-based therapies lie at the root of transplantation tolerance induction protocols. (
  • Having established the safety of Schwann cell transplantation in this initial group of subjects, the authors, as well as others, will now be better positioned to fully evaluate this approach and possibly combine it with other nascent therapies to amplify neurological recovery. (
  • Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation: Models in Discovery and Translation, Second Edition once again provides clinical and scientific researchers with a deep understanding of the current research in this field and the implications for translational practice. (
  • Because of this, allogeneic transplantation means that not only the donor's blood system but also his or her immune system is transferred. (
  • Unique among immune responses in terms of its strength and diversity, the T cell alloresponse reflects extensive genetic polymorphisms between allogeneic donors and recipients, most prominently within the major histocompatibility complex (MHC), which encodes human leukocyte antigens (HLAs) in humans. (
  • The benefits of immune restoration remain incompletely characterized but are known to be associated with reduced long-term mortality in general and decreased risk for malignancy specifically, particularly when the CD4 cell count is >500cells/mm3 [23-25]. (
  • More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes. (
  • The data provides evidence that the way a patient's immune system rebuilds itself following stem cell transplantation is representative of a dynamical system, a system in which the current state determines what future state will follow. (
  • HLA refers to the genes that encode for proteins on the surface of cells that are responsible for regulating the immune system. (
  • These mHA are protein fragments presented on the HLA molecules, which are the receptors on cells' surface to which these fragments of degraded proteins from within a cell bind in order to promote an immune response. (
  • T cells are a family of immune system cells that keep the body healthy by identifying and launching attacks against pathogens such as bacteria, viruses or cancer. (
  • Participants will undergo apheresis to collect lymphocytes (a type of white blood cell) for immune function tests. (
  • Although this important finding is unlikely to impact routine management of HIV infection, it does suggest that reconstitution of a host immune system with a population of mutant cells is a possible avenue of research to explore. (
  • Introduced the use of specific immune T cells to treat life-threatening viral infections. (
  • Introduced immune cell (T cell) depletion to prevent graft-versus-host disease (GVHD) - the most frequent complication after marrow transplantation. (
  • Immune system cells develop from special cells that live in the bone marrow called hematopoietic stem cells. (
  • The donor cells will live in the recipient's bone marrow and make blood and immune system cells. (
  • Immune system cells may be missing or just not work properly. (
  • The immune system uses HLA proteins on cells to help determine which cells belong to the body and which don't, so HLA matching increases the chances of transplanted donor cells being successfully incorporated into the recipient's body. (
  • Allogeneic hematopoietic stem cell transplantation involves transferring immune and haematopoietic system from a healthy donor to the recipient to treat haematological disorders such as leukaemia and lymphoma. (
  • In addition, it weakens the immune system, helping to prevent the rejection of donor marrow or stem cells. (
  • Mechanisms of immune evasion can involve abrogation of leukemia cell recognition due to the loss of HLA genes, immunosuppression by immune checkpoint ligand expression, production of anti-inflammatory factors, release of metabolically active enzymes, loss of pro-inflammatory cytokine production and acquisition of novel driver mutations that promote leukemia outgrowth. (
  • Since the establishment of the autoimmune etiology of type 1 DM in the late 1970s, many clinical trials analyzing the effects of different types of immune interventions demonstrated that beta-cell preservation is an achievable target in different degrees. (
  • The key observation that led to the emergence of nonmyeloablative allogeneic hematopoietic stem cell transplantation (NST) was the discovery of the immune-mediated allogeneic graft-versus-tumor (GVT) effect ( 4 , 5 ). (
  • The treatment that immediately precedes infusion of HSC is called conditioning therapy and is given to help kill tumour cells, "wipe out the memory" of the recipient's immune system, and create "space" within the bone marrow for the incoming stem cells to grow. (
  • Accurate determination of immune system compatibility is vital to minimise graft failure and lethal attack from donor cells against recipient's normal tissues (graft-versus-host disease or GvHD). (
  • hIDPSCs are immunologically privileged and can be used in the absence of any immune suppression protocol and have valuable cell therapy applications, including reconstruction of large cranial defects. (
  • Hematopoietic stem cell transplantation was first used as a treatment for some types of cancer but is now widely used as a therapy for various autoimmune diseases. (
  • A current definition of gene therapy is the infusion of a therapeutic gene, or cells transduced with the gene, in order to cure or prevent illnesses. (
  • Researchers in Milan, Italy re-examine the role of bone marrow stem cells in diabetic therapy and islet cell regeneration and Canadian researchers offer improved strategies for optimizing pancreatic islet culture in vitro. (
  • The success of cell therapy relies on effective delivery to the desired region," explained Dr. Marban. (
  • We now have a tool to determine whether stem cell therapy will be efficacious for an individual patient, not only for the heart but for any organ that received stem cell therapy. (
  • Hematopoietic stem cell transplantation (SCT) is emerging as a safe and effective therapy for HIV-infected persons with hematologic malignancies. (
  • Human immunodeficiency virus (HIV)-infected individuals are at increased risk for a range of hematologic cancers for which stem cell transplantation (SCT) is considered standard therapy. (
  • The Stem Cell Transplantation and Cellular Therapy Department offers specialized training for physicians interested in bone marrow transplantation and stem cell therapy. (
  • Identify appropriateness of stem cell product therapy, growth factor therapy and transfusion medicine as is relevant to transplantation. (
  • The conventional treatment is based on the correction of haemoglobin through regular red blood cell transfusions and treating the iron overload that develops subsequently with iron chelation therapy. (
  • Although, early detection and initiations of such supportive treatment has improved the quality of life for people with transfusion-dependent thalassaemia, allogeneic hematopoietic stem cell transplantation is the only widely available therapy with a curative potential. (
  • Randomised controlled trials and quasi-randomised controlled trials comparing hematopoietic stem cell transplantation with each other or with standard therapy (regular transfusion and chelation regimen). (
  • Transplantation of allogeneic (donated) stem cells is a mainstay of therapy for some forms of leukemia. (
  • Cell transplantation is a leading candidate therapy to repair tissue damage in the traumatically injured spinal cord. (
  • Washington, May 22 (ANI): Researchers from NewYork-Presbyterian Hospital/Weill Cornell Medical Centre suggest that genetically modifying stem cells prior to transplantation can help minimize the risk associated with the therapy. (
  • Stem cell therapy offers enormous potential to treat and even cure serious diseases. (
  • Researchers said that one of the biggest potential problems with stem cell therapy is the development of tumors. (
  • Once the future stem cell therapist does the therapy, stem cells have the innate potential to produce more cells," he added. (
  • This review will outline the current knowledge, including benefits and challenges, of the many current sources of stem cells for stroke therapy. (
  • Cherqui said that adult bone marrow stem cell therapy is particularly well suited as a potential treatment for cystinosis because these cells target all types of tissues. (
  • Cell Source, Inc. (OTC: CLCS) is a leading innovator of Veto Cell-based cellular therapy and immunotherapy technologies that are designed to provide safer and more accessible bone marrow transplantation, improve the treatment of blood cell cancers, facilitate treatment of genetic diseases, and allow for more accessible and successful organ transplantation by reducing or eliminating the need for lifelong, daily anti-rejection drugs. (
  • This project will contribute to the development of a combined therapy using stem cell grafts with rehabilitative training to optimize locomotor recovery after a severe injury. (
  • For this group, hematopoietic stem cell transplantation is considered one option of salvage therapy. (
  • The immediate post-transplantation course was uncomplicated and shortly afterwards his requirement for nasal desmopressin was reduced, presumably as a result of immunosuppressive therapy. (
  • Routine triple therapy immunosuppression (cyclosporin A, azathioprine, prednisolone) was maintained until 12 months after transplantation but azathioprine was then discontinued due to a persistently low white cell count. (
  • This novel cell therapy approach for treating subacute thoracic spinal cord injury is described in an article in Journal of Neurotrauma , a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. (
  • Stem cells are collected (harvested) before conditioning therapy starts and are usually frozen until it is time for use. (
  • Human IDPSCs can be easily derived from dental pulp extracted from adult or 'baby teeth' during routine dental visits," said study lead author Dr. Patricia C.B. Beltrao-Braga of the highly ranked National Institute of Science and Technology in Stem and Cell Therapy in Ribeirao Preto, Brazil. (
  • Contact: Dr. Patricia C.B. Beltrao-Braga, National Institute of Science and Technology in Stem Cell and Cell Therapy, 2051 Tenente Catao Roxo St. Ribeirao Preto, Brazil. (
  • Granulocytic sarcoma (GS) is a tumor consisting of malignant granulocytic precursor cells occurring at anatomical sites other than the bone marrow. (
  • Hematopoietic cell transplantation (HCT) is an important treatment modality for many benign and malignant hematologic disorders. (
  • HEMATOPOIETIC STEM CELL TRANSPLANTATION has been used for many years to treat various malignant and nonmalignant hematologic conditions. (
  • The first transplantation was performed in 1988, it is estimated that approximately 4,000 patients, with malignant and non-malignant diseases, were transplanted withcord blood transplantation. (
  • The discovery that the infusion of allogeneic hematopoietic stem cells can "rescue" patients from lethal marrow toxicity and give rise to a new donor-derived immunohematopoietic system resulted in successful treatments for patients with malignant or nonmalignant hematologic disease ( 2 , 3 ). (
  • De Waal LP and Van Twuyver E (1991) Blood transfusions and allograft survival: Is mixed chimerism the solution for tolerance induction in clinical transplantation? (
  • Therefore, to optimize clinical transplantation paradigms, researchers will need to monitor the cells' migration over time to determine the optimal parameters for transplantation. (
  • Identify a problem in clinical transplantation or basic science relevant to transplantation and execute a research project that is likely to lead to publication in a high-quality peer-reviewed journal. (
  • JSHCT was pivotal in orchestrating the computerization and unification of hematopoietic stem cell transplantation registries for the purpose of resolving these issues and providing a more accurate awareness of hematopoietic stem cell transplantations being performed in Japan. (
  • Since 1990 we have carried out more than 2,000 stem cell transplantations and thus represent one of the largest centers for allogeneic stem cell transplantations in Europe. (
  • In the new study, the researchers found that transplanted bone marrow stem cells carrying the normal lysosomal cystine transporter gene abundantly engrafted into every tissue of the experimental mice. (
  • Plasticell also announced collaboration with Anthony Nolan, a research organization in blood cancer, to progress clinical development of Plasticell's ex vivo expanded cord blood-derived hematopoietic stem cell product in December 2017. (
  • One of the disadvantage of cord blood is its low cell content which limits cord blood transplantation to generally low weight recipients, such as children. (
  • Alternative sources of haematopoietic stem cells, such as HLA mismatched (haplo-identical) family members and cord blood, may be available. (
  • The members of JSHCT are playing key-roles for steering JMDP (Japan Marrow Donor Program), JCBBN (Japan Cord Blood Bank Network), APBMT (Asia-Pacific Blood and Marrow Transplantation Group) and WBMT (Worldwide Network for Blood and Marrow Transplantation). (
  • It then moves on to discuss the immunobiology mechanisms that influence graft-versus-host disease (GVHD), graft-versus-leukemia effect, and transplantation success. (
  • Unfortunately, T lymphocytes are the same cells that cause graft versus host disease (GVHD) . (
  • Other factors such as difficulty in finding a donor for allogeneic transplantation, technological barriers (currently used culture technologies, point of care delivery, and lack of analytical assay), and side effects such as graft vs. host disease, are also expected to slow down growth of the hematopoietic stem cell transplantation market. (
  • Alloimmune T cells are central mediators of rejection and graft-versus-host disease in both solid organ and hematopoietic stem cell transplantation. (
  • Survival after allogeneic transplantation depends on donor-recipient matching, the graft-versus-host response, and the development of a graft versus leukemia effect. (
  • The fundamental obstacle of crossing the HLA barrier in haploidentical transplantation arises from the intense bidirectional responses from T-cells reacting to allogeneic HLA molecules resulting in overwhelmingly high incidence of GVHD and graft rejection. (
  • Collecting stem cells provides a bigger graft, and does not require that the donor be subjected to general anesthesia to collect the graft. (
  • Donor selection To avoid rejection of the transplanted stem cells or severe graft-versus-host disease , the donor should have the same human leukocyte antigens (HLA) as the recipient. (
  • In studies of contusion SCI in the rat using mitogen-expanded cells, we have shown that SC transplantation at seven days after injury significantly fosters axon regeneration and myelination, improves host tissue preservation, 4 and reduces cavitation 4,14 in a thoracic SCI paradigm and increases numbers of preserved NeuN positive neurons rostral and caudal to the injury/graft site 17 after cervical SCI. (
  • However, some patients develop a donor immunity-mediated disease known as graft-versus-host-disease following the transplantation. (
  • Further investigation revealed that an anti-microbial molecule called Lypd8, which is secreted by another type of colon cell and resides in the mucus, is lost in mice with disrupted inner mucus layer in graft-versus-host-disease. (
  • Goblet cells were specifically damaged in patients who developed graft-versus-host-disease, and severe goblet cell loss was associated with a poor survival following the transplantation. (
  • So, administration of IL-25 to protect patients' goblet cells could turn out to be a successful strategy against graft-versus-host-disease after allogeneic hematopoietic stem cell transplantation," said Daigo Hashimoto. (
  • Counting goblet cells using non-invasive methods, like confocal laser endomicroscopy, could also be used for diagnosing and monitoring graft-versus-host-disease," Takanori Teshima added. (
  • Sometimes the donor cells cause inflammation of the skin, liver and gut, and a reaction called graft-versus-host disease occurs. (
  • In 2006, 50,417 first HSCTs were recorded worldwide, according to a global survey of 1,327 centers in 71 countries conducted by the Worldwide Network for Blood and Marrow Transplantation. (
  • A recent study conducted in mice, baboons, and human volunteers has shown that a non-steroidal anti-inflammatory drug approved by the U.S. Food and Drug Administration (FDA), called meloxicam, significantly increased the number of blood (hematopoietic) stem cells (HSCs) and their descendent hematopoietic progenitor cells (HPCs) entering the circulation from the bone marrow, where they typically reside until needed. (
  • This finding sheds light on how the body responds to injury and has implications for blood cell transplantation. (
  • The levels of HSCs and HPCs normally found in blood are very low, and strategies have been devised to mobilize HSCs and progenitor cells out of the bone marrow and into the circulation. (
  • Firstly, hematopoietic stem cells (HSCs), or hemocytoblasts, are collected from the patient's bone marrow or blood and are frozen until they are needed. (
  • They have the ability to renew themselves and make different cells found in the blood. (
  • The patient's frozen HSCs are then thawed and re-infused into their blood, where they begin to make new red and white blood cells within 2 weeks. (
  • We analyzed the relationship between unrelated donor characteristics (age, sex, height, body weight, and complete blood count) and nucleated cell count concentration in harvested bone marrow between August 2007 and November 2015 at our hospital. (
  • 60 kg, it is possible to obtain adequate nucleated cell count by increasing their self-blood, even if their platelet counts are relatively low. (
  • As per survey by World Network for Blood and Marrow Transplantation (WBMN), around one million hematopoietic stem cell transplantation procedures were performed during 2006 to 2014, which indicates potential opportunities for market players. (
  • Researchers from the University of Maryland School of Medicine (UMSOM), the University of Pennsylvania and Emory University theorized that a blood test could be used to track the efficacy of transplanted stem cells. (
  • They aimed to achieve their goal by analyzing tiny cellular components called exosomes, secreted from the transplanted stem cells into the recipient blood. (
  • Through the blood test, which the researchers call a 'liquid biopsy,' the researchers monitored human cardiosphere-derived cells (CDCs) and cardiac progenitor cells (CPCs) transplanted into rat hearts following myocardial infarction. (
  • Paediatric Blood and Marrow Transplantation Program, Utrecht, The Netherlands. (
  • However, we recently reported that adult AML patients with GS had unique characteristics at the time of diagnosis, including younger age, higher white blood cell counts and higher frequency of French-British-American M4 and M5 morphology when compared with those without GS. (
  • Thomas' work showed that bone marrow cells infused intravenously could repopulate the bone marrow and produce new blood cells . (
  • For some types of blood diseases, transplantation is the standard of care. (
  • The donated tissue repopulated the marrow and restored production of the blood cells. (
  • The excess free α-globin chains precipitate in red blood cells, leading to their increased destruction (haemolysis) and ineffective erythropoiesis. (
  • Stem cells are cells produced by the bone marrow that mature into the different blood components-white cells, red cells and platelets. (
  • The lymphocytes are then separated and collected by a cell separator machine, and the rest of the blood is returned through a needle in the other arm. (
  • Your child can leave the hospital once your child's white blood cell count has recovered and s/he is no longer showing signs of side effects or infection. (
  • The blood is then collected by venipuncture and subjected to leukapheresis to obtain the cells for transplantation. (
  • Ray Owen at the University of Wisconsin made the early observation that a shared, naturally occurring neonatal blood supply was associated with the presence of chimeric red blood cell populations in adult cows ( 1 ). (
  • These cells produce the protective mucus layer that prevents intestinal bacteria from crossing into the intestinal tissue and blood stream. (
  • G-CSF helps the new stem cells do their normal work in the body;making new blood cells. (
  • You will receive G-CSF each day until your blood cell counts begin to recover to a certain level. (
  • You might be given blood transfusions if blood cell counts remain low. (
  • G-CSF, a growth factor that promotes the production of blood cells, will be injected under the skin once a day until your blood cell counts recover to a certain level. (
  • At the 13th Annual Meeting in 1991, when the 2nd Annual Meeting of Asia-Pacific Blood and Marrow Transplantation Group (APBMT) was jointly organized, the group expanded its membership to nurses and the other co-medicals, had the bylaws and elected the officers. (
  • Alveolar hemorrhage results from damage of the pulmonary microcirculation, loss of integrity in the alveolar-capillary basement membrane, and accumulation of red blood cells in the alveolar space ( 14 ). (
  • His course until two years after transplantation was uneventful with progressive improvement in lung function and arterial blood gas tensions until stable levels were achieved. (
  • Mild regimens are associated with no significant neutropenia (average neutrophil nadirs of ∼1,000/μl) and have minimal requirements for platelet or red blood cell transfusions. (
  • The eligibility criteria for a stem cell donor are essentially the same as for blood donation. (
  • The blood flows through a machine that removes the stem cells. (
  • The patient receives stem cells through a catheter placed into a blood vessel in the chest. (
  • Stem cells produce red blood cells, white blood cells, and platelets. (
  • If the stem cells will be from the donor's blood, the doctor will stick a needle in the donor's large vein or veins in the arms. (
  • This machine will spin the blood so that the stem cells are concentrated. (
  • The donor may also be required to take pills that cause more stem cells from the bone marrow to go into the blood. (
  • The goal of islet transplantation is to infuse enough islets to control the blood glucose level removing the need for insulin injections. (
  • Development and Application of Contemporary Immunosuppresion in Human Islet Transplantation. (
  • Improvements in isolation techniques and immunosuppressive regimens ushered in the first human islet transplantation clinical trials in the mid-1980s. (
  • In the study, the researchers used bone marrow stem cell transplantation to address symptoms of cystinosis in a mouse model. (
  • Seeking to improve stem cell transplantation to the retina, the researchers magnetized rat mesenchymal stem cells (MSCs) using superparamagnetic iron oxide nanoparticles (SPIONs). (
  • Predicting the storm: Can computer models improve stem cell transplantation? (
  • Human herpesvirus (HHV)-6 reactivation is common (30-50%) after allogeneic hematopoietic cell transplantation (allo-HCT), and is linked to various clinical manifestations. (
  • What is the optimal approach to prevent CMV infection in patients undergoing allogeneic hematopoietic cell transplantation (AHCT) in 2018? (
  • He has dedicated his career to serving the youngest patients, leading research and clinical progress in the treatment of childhood cancers including pediatric stem cell transplantation - experience that will prove invaluable to Cell Source as we continue the development of our Veto Cell platform technologies, which have recently transitioned into the first in human clinical trials. (
  • With the infusion of 5 million CD34+ cells, the recovery time for platelets to a target of 20,000/μL is possible within 2 weeks. (
  • Prior to becoming the Chair of the Department of Pediatrics and Director of Pediatric Hematology/Oncology in 2011, Dr. Rosenthal's earlier positions at City of Hope Medical Center included the Interim Chair of the Department of Pediatrics (2002 - 2011), Associate Professor and Director of Pediatric Hematopoietic Cell Transplantation (1996 - 2002), and Assistant Professor and Director of Pediatric Hematopoietic Cell Transplantation (1993 - 1995). (
  • Relapse remains the biggest challenge for cancer patients who have undergone stem cell transplantation. (
  • The hematopoietic niche of the bone marrow supports the survival and self-renewal of HSCs and HPCs, yet prevents the ill-timed release of these cells into the circulation. (
  • See 'The approach to hematopoietic cell transplantation survivorship' and 'Malignancy after hematopoietic cell transplantation' and 'Thalassemia: Management after hematopoietic cell transplantation' and 'Hematopoietic cell transplantation for aplastic anemia in adults', section on 'Late malignancy' and 'Hematopoietic cell transplantation for aplastic anemia in adults', section on 'Survival and quality of life' . (
  • The researchers performed in-depth analysis of the effects of labeling on the stem cells, including its effects on cell proliferation, differentiation, survival and electrophysiology. (
  • For the researchers, the 'easy availability' of BM, and that BM may offer "the ideal microenvironment for islet survival," suggest that exploring the possibility of using BM as the site for islet transplantation and they have started a clinical trial aimed at expanding on that idea. (
  • These factors must be controlled to avoid cell death and the optimization of islet culture must be assured to prolong the survival and functionality of the cells in vitro. (
  • The survival of islets after isolation remains a significant limiting factor in the field of islet transplantation. (
  • Ruben Mesa, MD, shares his thoughts on stem cell transplantation related to progression-free survival in MPNs, and Kathy Oubre highlights the importance of good working relationships. (
  • Curcumin preserves pancreatic islet cell survival and transplantation efficiency. (
  • A team of Italian researchers reports that employing BM-derived stem cells as "feeder tissue," playing a protective role in supporting pancreatic islet repair for clinical use in treating diabetes, presents new therapeutic possibilities. (
  • We found that magnetic attraction can focus iron-tagged therapeutic agents within a target region as we successfully used magnetism to counteract venous washout and improve cell retention in the contracting heart. (
  • Stem cell transplantation represents a promising therapeutic strategy, but transplantation of either neural progenitor cells or vascular cells has shown restricted therapeutic effectiveness. (
  • The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies. (
  • We recognize that stem cell derivations also provide uniquely individual difficulties and limitations in their therapeutic applications. (
  • Create healthcare diagrams like this example called Leukemia - Stem Cell Transplantation in minutes with SmartDraw. (
  • We excluded patients with hepatomegaly, splenomegaly or disseminated infiltration of leukemia cells in the skin and the infiltration in the cerebrospinal fluid that did not associated with tumors of the central nervous system. (
  • Donor cell leukemia: reappearance of gene mutations in donor cells - more than an incidental phenomenon? (
  • Wendy Stock, MD, is an expert in leukemia and stem cell transplantation. (
  • Alemtuzumab is a drug that is designed to specifically attack some types of leukemia and lymphoma cells. (
  • Additional evidence for the role of donor cells in GVT effects came from findings that recurrent leukemia could be successfully treated solely by infusing additional allogeneic lymphocytes ( 6 ). (
  • 2019) Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium. (
  • A study published by Cell Press June 19th in Stem Cell Reports reveals that simultaneous transplantation of neural and vascular progenitor cells can reduce stroke-related brain damage and improve behavioral recovery in rodents. (
  • They induced ischemic stroke in rats and then simultaneously injected neural and vascular progenitor cells from mice into the stroke-damaged rat brains 24 hours later. (
  • This is the first study to use embryonic stem cell-derived vascular progenitor cells together with neural progenitor cells to treat ischemic stroke," Gao says. (
  • Two weeks after stroke, rats that had undergone cotransplantation showed less brain damage and improved behavioral performance on motor tasks compared with rats that had been treated with neural progenitor cells alone. (
  • In contrast to more controversial stem cell transplantation, the new technique employs a subject's own progenitor cells, which are present in adults and are more restricted than stem cells in the type of tissues they can subsequently form. (
  • The role of telomere and telomerase are critical biological features of normal tissue stem and progenitor cells," said Dr. Rho. (
  • NICE's guidance on pancreatic islet cell transplantation has now been replaced. (
  • We recently demonstrated that pancreatic mensenchymal stromal cells (MSCs) originate from bone marrow cells," added Dr. Piemonti. (
  • There is mounting evidence that BM and BM-derived stem cells can participate in the regeneration of pancreatic isolates," concluded Dr. Piemonti. (